mexiletine has been researched along with Arrhythmia in 302 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mexiletine is a useful antiarrhythmic agent for the treatment of ventricular arrhythmias." | 10.15 | Oral mexiletine in the treatment of refractory ventricular arrhythmias: the role of electrophysiologic techniques. ( Garan, H; McGovern, B; Ruskin, JN; Schoenfeld, MH; Whitford, E, 1984) |
| "While mexiletine has been used for over 40 years for prevention of (recurrent) ventricular arrhythmias and for myotonia, patient access has recently been critically endangered." | 9.22 | Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review. ( Hollak, CEM; Jacobs, BAW; Postema, PG; Rosenberg, N; Stolwijk, N; van den Berg, S; van der Ree, MH; van der Wel, V; van Dussen, L; Wilde, AAM, 2022) |
| "To determine the spontaneous variability of ventricular arrhythmias (VA) and evaluate anti-arrhythmic efficacy of mexiletine, sotalol, and a mexiletine-sotalol combination in German shepherd dogs (GSD) with inherited arrhythmias." | 9.14 | Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German shepherd dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study. ( Gelzer, AR; Hemsley, SA; Kraus, MS; Moïse, NS; Rishniw, M, 2010) |
| "In a controlled randomized cross-over trial, 21 patients with coronary artery disease and frequent ventricular arrhythmias were studied to test the efficacy and tolerance of mexiletine 200 mg t." | 9.06 | [Anti-arrhythmia effectiveness and tolerance of retard in comparison with standard mexiletine]. ( Geibel, A; Hohnloser, S; Hust, M; Just, H; Meinertz, T; Zehender, M, 1987) |
| " The aim of the study was to investigate the effects of mexiletine on CA in patients with cor pulmonale in a state of cardio-respiratory decompensation." | 9.06 | The effects of mexiletine on cardiac arrhythmias in patients with cor pulmonale. ( Górecka, D; Skwarski, K; Sliwiński, P; Zieliński, J, 1989) |
| "The antiarrhythmic efficacy and safety of oral mexiletine hydrochloride and quinidine sulfate were compared at 29 clinical centers in a double-blind, parallel-group trial involving 491 patients with benign or potentially lethal ventricular arrhythmias." | 9.06 | Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias. ( Morganroth, J, 1987) |
| "The relationships between plasma mexiletine levels and the presence of ventricular arrhythmias and side effects were studied on patients from IMPACT (International Mexiletine and Placebo Antiarrhythmic Coronary Trial)." | 9.06 | Relationship between plasma mexiletine levels at steady-state. Presence of ventricular arrhythmias and side effects. ( Boissel, JP; Leizorovicz, A; Peyrieux, JC, 1987) |
| "The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction." | 9.05 | International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group. ( , 1984) |
| "Intravenous and oral mexiletine prophylaxis was compared with lignocaine supplemented placebo in a single blind trial in 240 high-risk patients with acute myocardial infarction." | 9.05 | A trial of intravenous and oral mexiletine in acute myocardial infarction. ( Doar, JW; Head, CD; Leggett, RJ; Smyllie, HC, 1984) |
| "The antiarrhythmic efficacy of mexiletine in acute myocardial infarction (AMI) was studied in 99 patients randomized to mexiletine or placebo treatment." | 9.05 | Antiarrhythmic efficacy of combined intravenous and oral mexiletine in acute myocardial infarction. A double blind placebo-controlled study. ( Halinen, MO; Helin, MJ; Pentikäinen, PJ; Rehnberg, S, 1984) |
| "Forty patients with serious lidocaine-responsive ventricular arrhythmias were randomly assigned to treatment with either oral disopyramide (100 mg 4 times daily) or mexiletine (200 mg 4 times daily) for 3 weeks." | 9.05 | Disopyramide and mexiletine: which is the agent of choice in the long term-oral treatment of lidocaine-responsive arrhythmias? Efficacy comparison in a randomized trial. ( Condorelli, M; De Luca, N; Rengo, F; Ricciardelli, B; Sacca', L; Trimarco, B; Volpe, M, 1980) |
| "We made an open comparison of lignocaine and mexiletine in the treatment of ventricular arrhythmias occurring after open-heart surgery." | 9.05 | Mexiletine vs. lignocaine in the management of ventricular arrhythmias after open-heart surgery. ( Bury, RW; Hale, G; Higginbotham, M; Mashford, ML; Zuidland, P, 1982) |
| "The incidence of ventricular arrhythmias after myocardial infarction has been compared in a controlled study of procainamide, mexiletine, and placebo." | 9.04 | Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction. ( Campbell, RW; Dolder, MA; Julian, DG; Murray, A; Prescott, LF; Talbot, RG, 1975) |
| "Twenty-four patients with ventricular arrhythmias were treated with oral mexiletine for periods of from one to 16 months (total 10." | 9.04 | Long-term treatment of ventricular arrhythmias with oral mexiletine. ( Julian, DG; Prescott, LF; Talbot, RG, 1976) |
| "We report a 28-year-old female patient with congenital type 2 long QT syndrome (LQTS) in which mexiletine shortened corrected QT interval (QTc) and effectively prevented refractory Torsade de Pointes (TdP) and ventricular fibrillation (VF)." | 8.12 | Mexiletine effectively prevented refractory Torsades de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome. ( Kai, K; Nakashima, R; Sakamoto, K; Takase, S; Tsutsui, H, 2022) |
| "Experimental studies and clinical reports suggest antiarrhythmic properties of mexiletine in different arrhythmias." | 7.88 | Broad antiarrhythmic effect of mexiletine in different arrhythmia models. ( Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Garthmann, J; Köbe, J; Kochhäuser, S; Reinke, F; Wasmer, K, 2018) |
| " He had taken mexiletine for 5 months, as he had been diagnosed with dilated cardiomyopathy and ventricular arrhythmia." | 7.76 | A case of mexiletine-induced hypersensitivity syndrome presenting as eosinophilic pneumonia. ( Kim, SH; Kim, TH; Lee, SP; Park, SS; Shin, DH; Sohn, JW; Yoon, HJ, 2010) |
| "We investigated effects of a new Na+ channel blocking antiarrhythmic drug, A-2545, N-3 (2,2,5,5-tetramethyl-3-pyrroline-3-carboxamido)-propyl-phthalimide-hydro chloride, on various canine ventricular automaticity arrhythmias induced by two-stage coronary ligation, digitalis and adrenaline, and compared them with those of mexiletine." | 7.70 | Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide. ( Arita, J; Aye, NN; Hashimoto, K; Xue, YX, 1998) |
| "We investigated the effects of (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate (Ro 22-9194), a novel class I antiarrhythmic agent, on myocardial ischemia- and reperfusion-induced arrhythmias in dogs." | 7.69 | Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory act ( Kanazawa, T; Kinukawa, M; Maruyama, K; Miyagi, M; Miyata, H; Murakami, M; Ujiie, A, 1996) |
| "The antiarrhythmic efficacy of mexiletine hydrochloride (Mexitil) was evaluated in 100 patients with potentially lethal and drug-resistant ventricular arrhythmia." | 7.68 | Mexiletine. Long-term efficacy and side effects in patients with chronic drug-resistant potentially lethal ventricular arrhythmias. ( Aragon, E; Faitel, K; Frumin, H; Kerin, NZ; Marinescu, G; Rubenfire, M, 1990) |
| "Mexiletine, an oral lidocaine-like drug, was initially thought to be effective treatment for recurring ventricular arrhythmias." | 7.67 | Mexiletine for recurring ventricular arrhythmias: assessment by long-term electrocardiographic recordings and sequential electrophysiologic studies. ( Alpert, MA; Flaker, GC; Madigan, NP; Moser, SA, 1984) |
| "Use of mexiletine was evaluated in 313 patients with ventricular tachyarrhythmias refractory to conventional antiarrhythmic drugs." | 7.67 | Long-term mexiletine for ventricular arrhythmia. ( Hirsowitz, G; Lampert, S; Lown, B; Podrid, PJ; Stein, J, 1984) |
| "Fifty-four patients with a symptomatic ventricular arrhythmia underwent two 24-hour electrocardiographic recordings, respectively before and after two to three weeks treatment with mexiletine, at a dose of 200 mg three times a day." | 7.67 | Effectiveness of mexiletine in ventricular arrhythmias. ( Chaudron, JM; Luwaert, RJ, 1985) |
| "We describe a case of acute myocardial infarction complicated by atrial and ventricular arrhythmias in which it was possible to verify the effectiveness of lidocaine, mexiletine and propafenone." | 7.67 | Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report. ( Aguglia, F; De Marzio, P; Gnecchi, M, 1985) |
| "The efficacy and safety of combined amiodarone and mexiletine treatment was investigated in 16 patients with chronic complex ventricular arrhythmias previously refractory to conventional antiarrhythmic agents and, in a lesser degree, to mexiletine or amiodarone." | 7.67 | [Anti-arrhythmic efficacy of the amiodarone-mexiletine combination in the treatment of resistant complex ventricular arrhythmias]. ( Bilancini, A; Blandini, A; Costantini, C; Curzi, G; Massacci, C; Pigini, G; Purcaro, A, 1986) |
| "Thirty mongrel dogs underwent proximal occlusion of the left anterior descending coronary artery to evaluate the comparative action of mexiletine and lidocaine on ventricular arrhythmias during myocardial reperfusion." | 7.67 | Effect of mexiletine on reperfusion-induced ventricular arrhythmias: comparison with lidocaine. ( Abete, P; Bonaduce, D; Canonico, V; Ferrara, N; Leosco, D; Longobardi, G; Morgano, G; Rengo, F, 1986) |
| "The effect of oral mexiletine therapy on ventricular arrhythmias was evaluated in 58 patients in whom conventional drugs had been unsuccessful." | 7.67 | Clinical evaluation of oral mexiletine therapy in the treatment of ventricular arrhythmias. ( Amsterdam, EA; Harris, F; Rutledge, JC, 1985) |
| "We studied the antiarrhythmic effect of oral Mexiletine in 20 patients with stable high-frequency ventricular arrhythmias refractory to therapeutic doses of conventional antiarrhythmic therapy." | 7.66 | [Mexiletine in treatment of chronic ventricular refractary arrhythmias (author's transl)]. ( Affinito, V; Ansalone, G; Bellocci, F; Loperfido, F; Lucente, M; Santarelli, P; Scabbia, E; Zecchi, P, 1981) |
| " bolus of 250 mg of mexiletine was checked in cases of acute myocardial infarction with ventricular premature beats." | 7.66 | [Antiarrhythmic treatment with mexiletine in acute myocardial infarction (author's transl)]. ( Codecà, L; Gruppillo, P; Masoni, A; Masoni, C; Padovan, GC, 1981) |
| "Mexiletine was administered during serial drug testing to 35 patients with electrically inducible ventricular arrhythmias and to 6 with recurrent ventricular tachycardia that could not be induced or terminated by programmed cardiac stimulation." | 7.66 | Mexiletine for refractory-ventricular arrhythmias: results using serial electrophysiologic testing. ( DiMarco, JP; Garan, H; Ruskin, JN, 1981) |
| "Oral mexiletine was begun immediately after completion of the intravenous infusion at a dose of 10 mg/kg/24 hr in the 10 responders to intravenous therapy." | 6.66 | Conversion from intravenous to oral mexiletine in the acute management of repetitive ventricular arrhythmia. ( Frye, SJ; Greenspan, AM; Horowitz, LN; Lowenthal, DT; Spielman, SR; Yacone, LA, 1985) |
| "Mexiletine efficacy was assessed in 14 patients (pts." | 6.66 | Mexiletine for the treatment of ventricular arrhythmias associated with chronic obstructive pulmonary disease. ( Farisè, F; Fracalossi, C; Lomanto, B; Marino, A; Moretti, L; Rossi, A; Ziacchi, V, 1989) |
| "Mexiletine is a new class I antiarrhythmic agent similar to lidocaine which when used orally may have significant gastric side effects." | 6.66 | Usefulness and safety of cimetidine in patients receiving mexiletine for ventricular arrhythmia. ( Klein, AL; Sami, MH, 1985) |
| "In Lidocaine treated group: 11 excellent (44%), 5 good (20%) and 9 ineffective (36%)." | 6.65 | [Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias]. ( Bonatti, V; Botti, G; Favaro, L; Finardi, A; Rolli, A, 1981) |
| " The high incidence of side-effects was probably due to the high dosage used." | 6.65 | Evaluation of the antiarrhythmic efficacy of mexiletine in patients with chronic ventricular arrhythmias. ( Van Durme, JP, 1980) |
| " In the dosage range 600 to 900 mg daily mexiletine effectively suppresses premature ventricular contractions (PVCs) in 25% to 79% of patients, with or without underlying cardiac disease." | 6.38 | Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. ( Brogden, RN; Monk, JP, 1990) |
| "Mexiletine is a new local anaesthetic antiarrhythmic agent whose chemical structure and electrophysiological properties closely resemble those of lignocaine although its anticonvulsant and pharmacokinetic properties differ from that drug." | 6.36 | Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias. ( Chew, CY; Collett, J; Singh, BN, 1979) |
| "A review of studies of mexiletine, a class I antiarrhythmic drug, supports its use in patients with ventricular arrhythmias or in sinus rhythm." | 6.15 | Hemodynamic effects of mexiletine. ( Shanks, RG, 1984) |
| "Mexiletine is a useful antiarrhythmic agent for the treatment of ventricular arrhythmias." | 6.15 | Oral mexiletine in the treatment of refractory ventricular arrhythmias: the role of electrophysiologic techniques. ( Garan, H; McGovern, B; Ruskin, JN; Schoenfeld, MH; Whitford, E, 1984) |
| "Amiodarone has pharmacokinetic interactions with various therapeutic agents, including phenytoin, flecainide, and cyclosporine." | 5.31 | Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. ( Hashimoto, H; Kamakura, S; Komamura, K; Matsumoto, K; Miyatake, K; Tachibana, M; Tanaka, K; Ueno, K; Yonezawa, E, 2002) |
| "Moricizine (moracizine) is a new class I antiarrythmic drug which is undergoing a large scale clinical trial at present." | 5.28 | The effect of pretreatment with moricizine on early arrhythmia resulting from myocardial ischemia in rats. ( Hashimoto, K; He, ZS; Komori, S; Tamura, K, 1992) |
| "Mexiletine was well absorbed from the intestinal tract." | 5.27 | Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias. ( Ebihara, A; Hashimoto, T; Hosoda, S; Kondo, K; Ohashi, K; Oka, T, 1984) |
| "Mexiletine was ineffective in 10 subjects." | 5.27 | Mexiletine in refractory ventricular arrhythmias. ( Fenster, PE; Kern, KB, 1983) |
| "Treatment of arrhythmias during pregnancy is complicated by insufficient information on the effects of the drug on the fetus or possible alterations of the drug's pharmacodynamics in the mother." | 5.27 | Mexiletine use in pregnancy and lactation. ( Ives, TJ; Lownes, HE, 1987) |
| "Mexiletine therapy was terminated for side effects in only five patients (12%)." | 5.27 | Mexiletine: an effective antiarrhythmic drug for treatment of ventricular arrhythmias in congenital heart disease. ( Garson, A; Moak, JP; Smith, RT, 1987) |
| "Mexiletine 10 microM was found to be very effective against all three types of arrhythmias in all three groups." | 5.27 | Electrophysiological mechanisms for the antiarrhythmic action of mexiletine on digitalis-, reperfusion- and reoxygenation-induced arrhythmias. ( Amerini, S; Carbonin, P; Cerbai, E; Giotti, A; Mugelli, A; Pahor, M, 1985) |
| "In four children the first signs of arrhythmias were seen a short time after viral infection." | 5.26 | [Mexiletine in the treatment of ventricular arrhythmias (author's transl)]. ( Schlemmer, M; Wimmer, M, 1982) |
| "Mexiletine appears to be an effective alternative to currently available antiarrhythmic agents." | 5.26 | Mexiletine in treatment of ventricular arrhythmias. A long-term follow-up. ( Hanson, A; Johansson, BW; Stavenow, L, 1979) |
| " The long therapeutic half-life of the drug allowed convenient dosage schedule and good compliance." | 5.26 | Mexiletine. Use in control of chronic drug-resistant ventricular arrhythmia. ( Abinader, EG; Cooper, M, 1979) |
| "While mexiletine has been used for over 40 years for prevention of (recurrent) ventricular arrhythmias and for myotonia, patient access has recently been critically endangered." | 5.22 | Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review. ( Hollak, CEM; Jacobs, BAW; Postema, PG; Rosenberg, N; Stolwijk, N; van den Berg, S; van der Ree, MH; van der Wel, V; van Dussen, L; Wilde, AAM, 2022) |
| "To determine the spontaneous variability of ventricular arrhythmias (VA) and evaluate anti-arrhythmic efficacy of mexiletine, sotalol, and a mexiletine-sotalol combination in German shepherd dogs (GSD) with inherited arrhythmias." | 5.14 | Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German shepherd dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study. ( Gelzer, AR; Hemsley, SA; Kraus, MS; Moïse, NS; Rishniw, M, 2010) |
| "Significant differences between pre- and posttreatment number of VPC, severity of arrhythmia, HR variables, or occurrence of syncope were not observed in dogs treated with atenolol or procainamide." | 5.10 | Comparison of the effects of four antiarrhythmic treatments for familial ventricular arrhythmias in Boxers. ( Atkins, CE; DeFrancesco, TC; Gordon, SG; Hamlin, RL; Keene, BW; Meurs, KM; Miller, MW; Moise, NS; Spier, AW; Wright, NA, 2002) |
| "In a controlled randomized cross-over trial, 21 patients with coronary artery disease and frequent ventricular arrhythmias were studied to test the efficacy and tolerance of mexiletine 200 mg t." | 5.06 | [Anti-arrhythmia effectiveness and tolerance of retard in comparison with standard mexiletine]. ( Geibel, A; Hohnloser, S; Hust, M; Just, H; Meinertz, T; Zehender, M, 1987) |
| "Thirty patients received one of the lidocaine analogues--mexiletine or tocainide--orally for treatment of symptomatic ventricular arrhythmias." | 5.06 | Mexiletine and tocainide: a comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing. ( Barbey, JT; Echt, DS; Kopelman, HA; Murray, KT; Roden, DM; Siddoway, LA; Woosley, RL, 1989) |
| " The aim of the study was to investigate the effects of mexiletine on CA in patients with cor pulmonale in a state of cardio-respiratory decompensation." | 5.06 | The effects of mexiletine on cardiac arrhythmias in patients with cor pulmonale. ( Górecka, D; Skwarski, K; Sliwiński, P; Zieliński, J, 1989) |
| "The antiarrhythmic efficacy and safety of oral mexiletine hydrochloride and quinidine sulfate were compared at 29 clinical centers in a double-blind, parallel-group trial involving 491 patients with benign or potentially lethal ventricular arrhythmias." | 5.06 | Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias. ( Morganroth, J, 1987) |
| "The relationships between plasma mexiletine levels and the presence of ventricular arrhythmias and side effects were studied on patients from IMPACT (International Mexiletine and Placebo Antiarrhythmic Coronary Trial)." | 5.06 | Relationship between plasma mexiletine levels at steady-state. Presence of ventricular arrhythmias and side effects. ( Boissel, JP; Leizorovicz, A; Peyrieux, JC, 1987) |
| "The antiarrhythmic effects of the sustained release form of mexiletine (Mexitil-Perlongets) were evaluated in a double-blind placebo trial in 630 patients with recent documented myocardial infarction." | 5.05 | International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group. ( , 1984) |
| "Intravenous and oral mexiletine prophylaxis was compared with lignocaine supplemented placebo in a single blind trial in 240 high-risk patients with acute myocardial infarction." | 5.05 | A trial of intravenous and oral mexiletine in acute myocardial infarction. ( Doar, JW; Head, CD; Leggett, RJ; Smyllie, HC, 1984) |
| "The antiarrhythmic efficacy of mexiletine in acute myocardial infarction (AMI) was studied in 99 patients randomized to mexiletine or placebo treatment." | 5.05 | Antiarrhythmic efficacy of combined intravenous and oral mexiletine in acute myocardial infarction. A double blind placebo-controlled study. ( Halinen, MO; Helin, MJ; Pentikäinen, PJ; Rehnberg, S, 1984) |
| "Oral long-term treatment with various antiarrhythmic drugs (aprindine, mexiletine, disopyramide, amiodarone) was assessed in 82 patients with recurrent tachycardias demonstrated in the ECG using programmed ventricular stimulation." | 5.05 | [Long-term drug therapy in ventricular cardiac arrhythmias. Is an improvement of the prognosis possible?]. ( Lüderitz, B; Manz, M; Steinbeck, G, 1983) |
| "In a controlled investigation on 84 patients with acute myocardial infarction, the effect of mexiletine on ectopic ventricular rhythms was tested with respect to mexiletine serum concentration." | 5.05 | [Mexiletin for treatment of ventricular ectopic rhythm in patients with acute myocardial infarction (author's transl)]. ( Brunner, H; Effert, S; Franken, G; Henning, B; Merx, W, 1980) |
| "Forty patients with serious lidocaine-responsive ventricular arrhythmias were randomly assigned to treatment with either oral disopyramide (100 mg 4 times daily) or mexiletine (200 mg 4 times daily) for 3 weeks." | 5.05 | Disopyramide and mexiletine: which is the agent of choice in the long term-oral treatment of lidocaine-responsive arrhythmias? Efficacy comparison in a randomized trial. ( Condorelli, M; De Luca, N; Rengo, F; Ricciardelli, B; Sacca', L; Trimarco, B; Volpe, M, 1980) |
| "We made an open comparison of lignocaine and mexiletine in the treatment of ventricular arrhythmias occurring after open-heart surgery." | 5.05 | Mexiletine vs. lignocaine in the management of ventricular arrhythmias after open-heart surgery. ( Bury, RW; Hale, G; Higginbotham, M; Mashford, ML; Zuidland, P, 1982) |
| "A double blind randomised study was undertaken comparing the effects of oral mexiletine and placebo given by general practitioners at home in the early stages of suspected acute myocardial infarction, and continued for six weeks." | 5.05 | A trial of prophylactic mexiletine in home coronary care. ( Bell, JA; Holt, DW; Isaacson, JR; Snell, NJ; Thomas, JM, 1982) |
| "The incidence of ventricular arrhythmias after myocardial infarction has been compared in a controlled study of procainamide, mexiletine, and placebo." | 5.04 | Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction. ( Campbell, RW; Dolder, MA; Julian, DG; Murray, A; Prescott, LF; Talbot, RG, 1975) |
| "Twenty-four patients with ventricular arrhythmias were treated with oral mexiletine for periods of from one to 16 months (total 10." | 5.04 | Long-term treatment of ventricular arrhythmias with oral mexiletine. ( Julian, DG; Prescott, LF; Talbot, RG, 1976) |
| "The anti-arrhythmic effect of oral mexiletine on exercise-induced ventricular arrhythmia was studied in a double blind trial of 10 patients suffering from ventricular ectopic beats of different origins." | 5.04 | Efficacy of oral mexiletine in the prevention of exercise-induced ventricular ectopic activity. ( Koch, G; Lindström, B, 1978) |
| "In a controlled study using mexiletine and placebo, the incidence of ventricular arrhythmias after acute myocardial infarction (AMI) has been compared." | 5.04 | [Frequency and prevention of ventricular arrhythmias after acute myocardial infarct]. ( Campbell, RW; Dolder, M; Julian, DG; Murray, A; Prescott, LE; Talbot, RG, 1976) |
| " Many of these therapies are older medications being given new roles such as mexiletine for Brugada syndrome and diflunisal for transthyretin amyloid cardiomyopathy." | 4.95 | Therapeutic Strategies Targeting Inherited Cardiomyopathies. ( Tang, WHW; Varian, K, 2017) |
| "Quinidine and procainamide have the potential for major organ toxicity, whereas mexiletine has been reported to have little risk of organ toxicity, serious proarrhythmia or congestive heart failure, but a relatively high incidence of nuisance side effects." | 4.78 | Comparative cost-effectiveness analysis of quinidine, procainamide and mexiletine. ( Arnold, RJ; Beck, JR; Beshansky, JR; Frishman, WH; Kaniecki, DJ; Kowey, PR; Podrid, PJ, 1991) |
| "We report a 28-year-old female patient with congenital type 2 long QT syndrome (LQTS) in which mexiletine shortened corrected QT interval (QTc) and effectively prevented refractory Torsade de Pointes (TdP) and ventricular fibrillation (VF)." | 4.12 | Mexiletine effectively prevented refractory Torsades de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome. ( Kai, K; Nakashima, R; Sakamoto, K; Takase, S; Tsutsui, H, 2022) |
| "Experimental studies and clinical reports suggest antiarrhythmic properties of mexiletine in different arrhythmias." | 3.88 | Broad antiarrhythmic effect of mexiletine in different arrhythmia models. ( Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Garthmann, J; Köbe, J; Kochhäuser, S; Reinke, F; Wasmer, K, 2018) |
| "Antiarrhythmic agents which belong to class Ia (quinidine) and Ic (flecainide) reportedly increase propensity to ventricular tachyarrhythmia, whereas class Ib agents (lidocaine and mexiletine) are recognized as safe antiarrhythmics." | 3.80 | Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization. ( Osadchii, OE, 2014) |
| " He had taken mexiletine for 5 months, as he had been diagnosed with dilated cardiomyopathy and ventricular arrhythmia." | 3.76 | A case of mexiletine-induced hypersensitivity syndrome presenting as eosinophilic pneumonia. ( Kim, SH; Kim, TH; Lee, SP; Park, SS; Shin, DH; Sohn, JW; Yoon, HJ, 2010) |
| "We investigated effects of a new Na+ channel blocking antiarrhythmic drug, A-2545, N-3 (2,2,5,5-tetramethyl-3-pyrroline-3-carboxamido)-propyl-phthalimide-hydro chloride, on various canine ventricular automaticity arrhythmias induced by two-stage coronary ligation, digitalis and adrenaline, and compared them with those of mexiletine." | 3.70 | Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide. ( Arita, J; Aye, NN; Hashimoto, K; Xue, YX, 1998) |
| "We investigated the effects of (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate (Ro 22-9194), a novel class I antiarrhythmic agent, on myocardial ischemia- and reperfusion-induced arrhythmias in dogs." | 3.69 | Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory act ( Kanazawa, T; Kinukawa, M; Maruyama, K; Miyagi, M; Miyata, H; Murakami, M; Ujiie, A, 1996) |
| " So we continued synthesis and evaluation of a series of 5-substituted 5,11-dihydro[1]benzoxepino[3,4-b]pyridines for antiarrhythmic activity in chloroform-induced ventricular arrhythmias in mice and in ouabain-induced ventricular arrhythmias in dogs." | 3.68 | Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines. ( Harakawa, H; Ishii, A; Kubo, K; Kumazawa, T; Nito, M; Obase, H; Oiji, Y; Tomioka, S; Yamada, Y, 1990) |
| "The electrophysiological effects of combination therapy of mexiletine and propafenone were assessed using standard 12-lead electrocardiogram (standard ECG), signal-averaged ECG (SAECG), and ambulatory ECG in 31 patients with ventricular arrhythmias." | 3.68 | Mexiletine and propafenone: a comparative study of monotherapy, low, and full dose combination therapy. ( Haruna, M; Kato, H; Lee, S; Machii, T; Nonokawa, M; Takanaka, C; Yabe, S, 1992) |
| " RS-2135 exerted more potent antiarrhythmic activity than reference compounds against ouabain-induced arrhythmias in dogs." | 3.68 | Antiarrhythmic and cardiovascular profiles of the fused indole compound (3aR,12R,12aR,12bS)-12-amino-2,3,3a,4,11,12,12a,12b-octahydro-10-hydrox yisoquino [2,1,8-lma]carbazol-5(1H)-one hydrochloride 1.5 hydrate. ( Fukami, M; Hashimoto, T; Itoh, Y; Koike, H; Kumakura, S; Miyake, S; Mizuno, H; Shiga, H; Shimoji, Y; Yorikane, R, 1991) |
| "The indole-derived compounds, which possessed side chains resembling those of changrolin (4-[3',5'-bis[(N-pyrrolidinyl)methyl]-4'-hydroxyaniline]-quinazoline) showed potent anti-arrhythmic activity by restoration of sinus rhythm from ouabain-induced tachycardia in guinea pigs." | 3.68 | Anti-arrhythmic activities of six indole derivatives of changrolin. ( Chen, YH; Cheng, JH; Dai, DZ; Huang, J; Huang, WL; Liu, J; Peng, SX; Qiu, YT; Rong, P, 1991) |
| "Ventricular arrhythmia suppression trials were performed to compare the efficacies and side effects of disopyramide and mexiletine used alone and in combination, and to compare the efficacies and side effects of mexiletine and propranolol used alone and in combination, in patients with chronic ventricular premature contractions (VPCs, greater than or equal to 3000 beats/day)." | 3.68 | Combination antiarrhythmic treatment among class Ia, Ib, and II agents for ventricular arrhythmias. ( Tanabe, T, 1991) |
| "The antiarrhythmic efficacy of mexiletine hydrochloride (Mexitil) was evaluated in 100 patients with potentially lethal and drug-resistant ventricular arrhythmia." | 3.68 | Mexiletine. Long-term efficacy and side effects in patients with chronic drug-resistant potentially lethal ventricular arrhythmias. ( Aragon, E; Faitel, K; Frumin, H; Kerin, NZ; Marinescu, G; Rubenfire, M, 1990) |
| " The new compounds of each type were active against aconitine-induced arrhythmia and several of them had higher activity and better chemotherapeutic index than quinidine." | 3.67 | New antiarrhythmic agents. 2,2,5,5-Tetramethyl-3-pyrroline-3-carboxamides and 2,2,5,5-tetramethylpyrrolidine-3-carboxamindes. ( Bódi, I; Frank, L; Hankovszky, OH; Hideg, K, 1986) |
| "Mexiletine, an oral lidocaine-like drug, was initially thought to be effective treatment for recurring ventricular arrhythmias." | 3.67 | Mexiletine for recurring ventricular arrhythmias: assessment by long-term electrocardiographic recordings and sequential electrophysiologic studies. ( Alpert, MA; Flaker, GC; Madigan, NP; Moser, SA, 1984) |
| "6 mg/min for 4-40 hrs), Propafenone (1-2 mg/Kg in 5 min + continuous infusion of 10-15 mcg/Kg/min for 24 hrs) and Mexiletine (250 mg in 15 min + 250 mg in 1 hr) have been evaluated in patients with acute myocardial infarction complicated by sinus tachycardia and hyperdynamic pattern, ventricular or supraventricular arrhythmias." | 3.67 | Hemodynamic effects of antiarrhythmic drugs in acute myocardial infarction. ( Ambrosini, F; Finzi, A; Lo Masto, M; Lotto, A; Massari, FM; Pagnoni, F; Valentini, R, 1984) |
| "Use of mexiletine was evaluated in 313 patients with ventricular tachyarrhythmias refractory to conventional antiarrhythmic drugs." | 3.67 | Long-term mexiletine for ventricular arrhythmia. ( Hirsowitz, G; Lampert, S; Lown, B; Podrid, PJ; Stein, J, 1984) |
| "In order to evaluate and compare slow-release mexiletine 360 mg 12 hourly and conventional mexiletine 200 mg 8 hourly, twelve patients with symptomatic ventricular arrhythmias have been studied." | 3.67 | A study to compare the efficacy, plasma concentration profile and tolerability of conventional mexiletine and slow-release mexiletine. ( Holt, DW; Jackson, G; Upward, JW, 1984) |
| "Fifty-four patients with a symptomatic ventricular arrhythmia underwent two 24-hour electrocardiographic recordings, respectively before and after two to three weeks treatment with mexiletine, at a dose of 200 mg three times a day." | 3.67 | Effectiveness of mexiletine in ventricular arrhythmias. ( Chaudron, JM; Luwaert, RJ, 1985) |
| "We describe a case of acute myocardial infarction complicated by atrial and ventricular arrhythmias in which it was possible to verify the effectiveness of lidocaine, mexiletine and propafenone." | 3.67 | Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report. ( Aguglia, F; De Marzio, P; Gnecchi, M, 1985) |
| "We monitored the plasma levels of mexiletine in 20 dialysis patients with severe cardiac arrhythmias after repeated oral administration and the elimination by various dialysis procedures." | 3.67 | [Mexiletine in terminal renal failure and various dialysis procedures]. ( Aboudan, F; Evers, J; Finke, K; Messer, W, 1989) |
| "In a controlled crossover trial, 15 patients with frequent ventricular arrhythmias were treated with lidocaine to predict efficacy and safety of oral mexiletine." | 3.67 | Prediction of efficacy and tolerance of oral mexiletine by intravenous lidocaine application. ( Geibel, A; Hohnloser, S; Just, H; Meinertz, T; Treese, N; Zehender, M, 1988) |
| " The antiarrhythmic potency of propafenone was evaluated in the guinea-pig isolated heart; arrhythmias were induced with (a) digitalis intoxication and (b) hypoxia followed by reoxygenation." | 3.67 | Electrophysiological mechanism for the antiarrhythmic action of propafenone: a comparison with mexiletine. ( Amerini, S; Bernabei, R; Carbonin, P; Cerbai, E; Mugelli, A; Pahor, M, 1988) |
| "The efficacy of disopyramide (DP), mexiletine (MX), aprindine (AP) and cibenzoline (CZ) on ventricular arrhythmias was compared (single drug therapy)." | 3.67 | Therapeutic effectiveness and plasma levels of single or combination use of class I antiarrhythmic agents for ventricular arrhythmias. ( Furuya, H; Goto, Y; Tanabe, T; Yoshikawa, H, 1988) |
| " GYKI-23 107 was effective against chemically (aconitine and ouabain) induced arrhythmias after both parenteral and oral administration." | 3.67 | Pharmacological investigation of a new anti-arrhythmic agent, GYKI-23 107. ( Jaszlits, L; Kürthy, M; Rabloczky, G; Toldy, L; Varró, A; Zubovics, Z, 1987) |
| " route proved to be more potent and longer-acting than disopyramide, propaphenone and mexiletine against supraventricular and ventricular arrhythmias induced by chloroform, aconitine, ouabain and halothane-adrenaline." | 3.67 | Antiarrhythmic effects of a novel diamine derivative, AN-132, on several animal models of cardiac arrhythmias. ( Sakai, K; Takagi, M; Yamazaki, T, 1987) |
| "In an acute experiment in healthy volunteers and in patients under long-term treatment for cardiac arrhythmias, mexiletine inhibits caffeine elimination by about 50%." | 3.67 | Influence of mexiletine on caffeine elimination. ( Epping, J; Heusler, H; Joeres, R; Klinker, H; Richter, E, 1987) |
| "The efficacy and safety of combined amiodarone and mexiletine treatment was investigated in 16 patients with chronic complex ventricular arrhythmias previously refractory to conventional antiarrhythmic agents and, in a lesser degree, to mexiletine or amiodarone." | 3.67 | [Anti-arrhythmic efficacy of the amiodarone-mexiletine combination in the treatment of resistant complex ventricular arrhythmias]. ( Bilancini, A; Blandini, A; Costantini, C; Curzi, G; Massacci, C; Pigini, G; Purcaro, A, 1986) |
| "Thirty mongrel dogs underwent proximal occlusion of the left anterior descending coronary artery to evaluate the comparative action of mexiletine and lidocaine on ventricular arrhythmias during myocardial reperfusion." | 3.67 | Effect of mexiletine on reperfusion-induced ventricular arrhythmias: comparison with lidocaine. ( Abete, P; Bonaduce, D; Canonico, V; Ferrara, N; Leosco, D; Longobardi, G; Morgano, G; Rengo, F, 1986) |
| "18 patients with myocardial infarction complicated by severe ventricular arrhythmias (polymorphic VEBs or bigeminy = 5; VT = 11; VF = 2) were treated with antiarrhythmics which were stopped after 24 hours (intravenous infusion of mexiletine 0." | 3.67 | [Early interruption of antiarrhythmia treatment in the acute phase of infarction complicated by ventricular arrhythmia]. ( Farinotti, R; Gryman, R; Guérot, C; Khemache, A; Sebbah, J; Valère, PE, 1985) |
| "To determine whether failure of procainamide to prevent initiation of ventricular tachyarrhythmias during electrophysiologic testing predicted failure of other antiarrhythmic regimens, 81 consecutive patients with coronary artery disease whose ventricular tachyarrhythmias remained inducible during procainamide administration were studied." | 3.67 | Limitations of failure of procainamide during electrophysiologic testing to predict response to other medical therapy. ( Greenspan, AM; Horowitz, LN; Rae, AP; Sokoloff, NM; Spielman, SR; Webb, CR, 1985) |
| "The effect of oral mexiletine therapy on ventricular arrhythmias was evaluated in 58 patients in whom conventional drugs had been unsuccessful." | 3.67 | Clinical evaluation of oral mexiletine therapy in the treatment of ventricular arrhythmias. ( Amsterdam, EA; Harris, F; Rutledge, JC, 1985) |
| " Mexiletine increased the dose of ouabain required for the occurrence of arrhythmia and cardiac arrest." | 3.67 | Inhibition of sympathetic nervous system by mexiletine, an antiarrhythmic agent, and its antagonism against ouabain. ( Kitagawa, H; Kohei, H; Takeda, F, 1985) |
| "We studied the antiarrhythmic effect of oral Mexiletine in 20 patients with stable high-frequency ventricular arrhythmias refractory to therapeutic doses of conventional antiarrhythmic therapy." | 3.66 | [Mexiletine in treatment of chronic ventricular refractary arrhythmias (author's transl)]. ( Affinito, V; Ansalone, G; Bellocci, F; Loperfido, F; Lucente, M; Santarelli, P; Scabbia, E; Zecchi, P, 1981) |
| "The clinical relevance of changes in pharmacokinetics of oral mexiletine (600 mg daily dose) was studied in 82 patients with ventricular arrhythmias and impaired liver, renal or heart function (control group n = 51, patients with liver cirrhosis n = 9, with renal insufficiency n = 14, or heart failure n = 8)." | 3.66 | Increase of mexiletine plasma levels due to delayed hepatic metabolism in patients with chronic liver disease. ( Lüderitz, B; Nitsch, J; Steinbeck, G, 1983) |
| "A new data analysis approach, NON-MEM, proposed by Sheiner and Beal, has been employed to estimate the population pharmacokinetic parameters of oral mexiletine in patients treated for arrhythmias." | 3.66 | Population pharmacokinetic parameters in patients treated with oral mexiletine. ( Follath, F; Katz, G; Steiner, V; Vozeh, S, 1982) |
| "The effects of the antiarrhythmic drugs disopyramide (D), mexiletine (M), and propafenone (P) on left ventricular function after intravenous injection and after oral therapy of at least 48 hours, and of the combined oral application of D and M, were studied by M-mode echocardiography in patients with ventricular arrhythmias in whom antiarrhythmic therapy was indicated." | 3.66 | [The effect of disopyramide, mexiletine and propafenon after intravenous and oral administration on left ventricular function in the M-mode echocardiogram]. ( Böcker, K; Köhler, E; Loogen, F; Seipel, L, 1982) |
| " bolus of 250 mg of mexiletine was checked in cases of acute myocardial infarction with ventricular premature beats." | 3.66 | [Antiarrhythmic treatment with mexiletine in acute myocardial infarction (author's transl)]. ( Codecà, L; Gruppillo, P; Masoni, A; Masoni, C; Padovan, GC, 1981) |
| "Mexiletine was administered during serial drug testing to 35 patients with electrically inducible ventricular arrhythmias and to 6 with recurrent ventricular tachycardia that could not be induced or terminated by programmed cardiac stimulation." | 3.66 | Mexiletine for refractory-ventricular arrhythmias: results using serial electrophysiologic testing. ( DiMarco, JP; Garan, H; Ruskin, JN, 1981) |
| "Forty-eight patients with ischaemic heart disease received oral mexiletine for the control or prevention of ventricular arrhythmias." | 3.66 | Long-term oral antiarrhythmic therapy with mexiletine. ( Adgey, AA; Campbell, NP; Pantridge, JF, 1978) |
| "Mexiletine is an antiarrhythmic drug belonging to IB class, acting as sodium channel blocker." | 2.72 | Voltage-Gated Sodium Channel Blockers: Synthesis of Mexiletine Analogues and Homologues. ( Carocci, A; Catalano, A; Franchini, C, 2021) |
| "Oral mexiletine was begun immediately after completion of the intravenous infusion at a dose of 10 mg/kg/24 hr in the 10 responders to intravenous therapy." | 2.66 | Conversion from intravenous to oral mexiletine in the acute management of repetitive ventricular arrhythmia. ( Frye, SJ; Greenspan, AM; Horowitz, LN; Lowenthal, DT; Spielman, SR; Yacone, LA, 1985) |
| "Mexiletine efficacy was assessed in 14 patients (pts." | 2.66 | Mexiletine for the treatment of ventricular arrhythmias associated with chronic obstructive pulmonary disease. ( Farisè, F; Fracalossi, C; Lomanto, B; Marino, A; Moretti, L; Rossi, A; Ziacchi, V, 1989) |
| "Mexiletine is a new class I antiarrhythmic agent similar to lidocaine which when used orally may have significant gastric side effects." | 2.66 | Usefulness and safety of cimetidine in patients receiving mexiletine for ventricular arrhythmia. ( Klein, AL; Sami, MH, 1985) |
| "In Lidocaine treated group: 11 excellent (44%), 5 good (20%) and 9 ineffective (36%)." | 2.65 | [Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias]. ( Bonatti, V; Botti, G; Favaro, L; Finardi, A; Rolli, A, 1981) |
| "Many sudden deaths are presumed to be due to an arrhythmia, but the drugs best known for antiarrhythmic activity, the local anesthetic agents, have not been suitable prophylactic agents because of their toxicities and other undesirable pharmacologic characteristics." | 2.65 | Selection of an antiarrhythmic drug for a sudden-death-prevention trial. ( Duff, HJ; Oates, JA; Roden, DM; Woosley, RL, 1982) |
| " The high incidence of side-effects was probably due to the high dosage used." | 2.65 | Evaluation of the antiarrhythmic efficacy of mexiletine in patients with chronic ventricular arrhythmias. ( Van Durme, JP, 1980) |
| "It is effective against ventricular arrhythmias, both parenterally and orally, and has been used in acute myocardial infarction, in the convalescence following myocardial infarction and in ventricular arrhythmias of different aetiology." | 2.65 | Mexiletine in clinical practice. ( Boyle, DM, 1980) |
| "Mexiletine is an oral class IB antiarrhythmic agent." | 2.53 | Antiarrhythmic Mexiletine: A Review on Synthetic Routes to Racemic and Homochiral Mexiletine and its Enantioseparation. ( Carocci, A; Catalano, A, 2016) |
| "Mexiletine is a Class IB antiarrhythmic which has basic and clinical electrophysiologic properties similar to lidocaine." | 2.38 | Mexiletine: pharmacology and therapeutic use. ( Cameron, J; Deering, TF; Estes, NA; Manolis, AS, 1990) |
| " In the dosage range 600 to 900 mg daily mexiletine effectively suppresses premature ventricular contractions (PVCs) in 25% to 79% of patients, with or without underlying cardiac disease." | 2.38 | Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias. ( Brogden, RN; Monk, JP, 1990) |
| "Mexiletine is a class I antiarrhythmic agent that is active after both oral and intravenous administration and similar in structure and activity to lidocaine." | 2.37 | Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. ( Cerskus, I; Duff, HJ; Roden, D; Siddoway, L; Stone, W; Thompson, K; Wang, T; Woosley, RL, 1984) |
| " Serious adverse reactions necessitate a change in antiarrhythmic therapy, as opposed to lowering drug dosage to an ineffective level." | 2.37 | Antiarrhythmic drug therapy. Recent advances and current status. ( Somberg, J, 1985) |
| "The frequency of ventricular arrhythmias increases with age." | 2.37 | Cardiac arrhythmias in the elderly: antiarrhythmic drug treatment. ( Morganroth, J; Nestico, PF, 1986) |
| "While treatment of ventricular arrhythmias is completely justifiable for patients with symptoms, their use to prevent sudden cardiac death has not yet been established." | 2.37 | Antiarrhythmic agents for chronic ventricular arrhythmias. ( Morganroth, J; Nestico, PF, 1987) |
| "Cardiac arrhythmias may be caused by abnormalities of impulse initiation, impulse propagation, or a combination of the two." | 2.36 | Electropharmacology of antiarrhythmic drugs. ( Rosen, MR; Wit, AL, 1983) |
| "Mexiletine is a new local anaesthetic antiarrhythmic agent whose chemical structure and electrophysiological properties closely resemble those of lignocaine although its anticonvulsant and pharmacokinetic properties differ from that drug." | 2.36 | Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias. ( Chew, CY; Collett, J; Singh, BN, 1979) |
| "Mexiletine is a Class 1B antiarrhythmic drug that causes the disappearance of T-wave alternans by shortening QTc and peak-to-end of the T wave." | 1.48 | A case report: Is mexiletine usage effective in the shortening of QTC interval and improving the T-wave alternans in Timothy syndrome? ( Ergul, Y; Tunca Sahin, G, 2018) |
| "Thousands die each year from sudden infant death syndrome (SIDS)." | 1.33 | A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y. ( Bowers, PN; Chen, W; Goldstein, SA; Kittles, RA; Liu, Q; Morgan, T; Plant, LD; State, MW; Zhang, T, 2006) |
| "Mutations in SCN5A cause arrhythmia syndromes including Brugada syndrome (BrS) and congenital long QT syndrome subtype 3 (LQT3)." | 1.32 | A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs. ( Ackerman, MJ; Jahangir, A; Makielski, JC; Munger, TM; Porter, CB; Rok, BA; Tester, DJ; Valdivia, CR, 2004) |
| "Amiodarone has pharmacokinetic interactions with various therapeutic agents, including phenytoin, flecainide, and cyclosporine." | 1.31 | Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients. ( Hashimoto, H; Kamakura, S; Komamura, K; Matsumoto, K; Miyatake, K; Tachibana, M; Tanaka, K; Ueno, K; Yonezawa, E, 2002) |
| " The final pharmacokinetic parameters are, CL/F=0." | 1.30 | Population pharmacokinetic analysis of mexiletine in adult arrhythmic patients in Japanese population. ( Iwai, T; Koue, T; Shibakawa, M; Uenaka, K; Ueno, K, 1998) |
| " During dosing (10 mg kg-1 twice a day for 10 days) no effects on the electrocardiogram, monitored in conscious animals, were observed despite modest reductions (15-18%) in the maximum rate of depolarization of papillary muscle excised 1 or 6 h after completion of the dosing regime." | 1.28 | Antiarrhythmic, electrophysiological and haemodynamic effects of prolonged oral dosing with Org 7797 in the anaesthetized rat. ( Delbressine, L; Harris, N; Kane, KA; Muir, AW; Winslow, E, 1992) |
| "Moricizine (moracizine) is a new class I antiarrythmic drug which is undergoing a large scale clinical trial at present." | 1.28 | The effect of pretreatment with moricizine on early arrhythmia resulting from myocardial ischemia in rats. ( Hashimoto, K; He, ZS; Komori, S; Tamura, K, 1992) |
| "Treatment with aprindine or mexiletine was effective in 7 (50%) of the 14 patients who did not respond to procainamide and/or disopyramide." | 1.28 | Analysis of ventricular arrhythmias in patients with dilated cardiomyopathy--relationship between the effects of antiarrhythmic agents and severity of myocardial lesions. ( Fukuzaki, H; Takarada, A; Yokota, Y, 1990) |
| "Mexiletine is a type 1B antiarrhythmic drug similar to lidocaine." | 1.28 | Prolongation of ventricular depolarization. ECG manifestation of mexiletine toxicity. ( Chandrasekaran, K; Hammill, SC; Nora, MO; Reeder, GS, 1989) |
| " In all instances adverse effects emerged before ectopic activity was suppressed satisfactorily prohibiting further increment of dosage." | 1.27 | Increased incidence of side effects after encainide: a newly developed antiarrhythmic drug. ( Berchtold-Kanz, E; Hust, M; Just, H; Nitsche, K; Schwarz, G, 1984) |
| "Malignant ventricular arrhythmias often occur in patients with left ventricular (LV) dysfunction." | 1.27 | Effects of oral mexiletine on left and right ventricular function. ( Lown, B; Podrid, P; Stein, J, 1984) |
| "Mexiletine was well absorbed from the intestinal tract." | 1.27 | Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias. ( Ebihara, A; Hashimoto, T; Hosoda, S; Kondo, K; Ohashi, K; Oka, T, 1984) |
| "Mexiletine was ineffective in 10 subjects." | 1.27 | Mexiletine in refractory ventricular arrhythmias. ( Fenster, PE; Kern, KB, 1983) |
| "Mexiletine was given to 12 patients for different periods of time varying from 4 to 96 months, with a mean of 47." | 1.27 | Long-term clinical experience with mexiletine. ( Hanson, A; Johansson, BW; Stavenow, L, 1984) |
| "Phenytoin was effective on three arrhythmias and its min PCs were 9." | 1.27 | Quantitative analysis of the antiarrhythmic effect of drugs on canine ventricular arrhythmias by the determination of minimum effective plasma concentrations. ( Hashimoto, K; Imai, S; Satoh, H; Shibuya, T, 1983) |
| " In the four volunteers, acute dosage with the 432-mg preparation produced a markedly lower peak mexiletine concentration and fewer side effects than did two 200-mg capsules." | 1.27 | Absorption and antiarrhythmic efficacy of sustained-release mexiletine. ( Campbell, RW; Chadwick, DE; Holt, DW, 1983) |
| "Mexiletine and tocainide were administered to 79 patients to determine whether the response to one of these drugs would predict the effect of the other." | 1.27 | Mexiletine and tocainide: does response to one predict response to the other? ( Blum, R; Hession, M; Lampert, S; Lown, B; Podrid, PJ; Stein, J, 1986) |
| "Propafenone has significantly improved our ability to control postoperative JET." | 1.27 | Newer antiarrhythmic drugs in children. ( Garson, A; Moak, JP; Smith, RT, 1987) |
| "Aggravation of ventricular arrhythmia is a serious, potentially lethal, side effect that can occur with all antiarrhythmic agents." | 1.27 | Clinical predictors of arrhythmia worsening by antiarrhythmic drugs. ( Lampert, S; Lown, B; Podrid, PJ; Slater, W, 1988) |
| "Verapamil was more effective than diltiazem." | 1.27 | Comparison of the effects of calcium channel blockers and antiarrhythmic drugs on digitalis-induced oscillatory afterpotentials on canine Purkinje fiber. ( Endou, K; Sato, T; Yamamoto, H, 1987) |
| "Treatment of arrhythmias during pregnancy is complicated by insufficient information on the effects of the drug on the fetus or possible alterations of the drug's pharmacodynamics in the mother." | 1.27 | Mexiletine use in pregnancy and lactation. ( Ives, TJ; Lownes, HE, 1987) |
| "Mexiletine therapy was terminated for side effects in only five patients (12%)." | 1.27 | Mexiletine: an effective antiarrhythmic drug for treatment of ventricular arrhythmias in congenital heart disease. ( Garson, A; Moak, JP; Smith, RT, 1987) |
| "Amiodarone was the only one of the four drugs that caused a substantial reduction of ventricular premature complexes (logarithmic mean 97." | 1.27 | Comparative antiarrhythmic efficacy of verapamil, 17-monochloracetylajmaline, mexiletine and amiodarone in patients with severe chagasic myocarditis: relation with the underlying arrhythmogenic mechanisms. ( Bandieri, JD; Chiale, PA; Elizari, MV; Haedo, AH; Lázzari, JO; Rosenbaum, MB, 1986) |
| "Protection from arrhythmias seems to be related to the combined presence of a noncompetitive adrenergic blockade associated with salutary effects on coronary circulation." | 1.27 | The effect of antiarrhythmic drugs on life-threatening arrhythmias induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity. ( Schwartz, PJ; Vanoli, E; Zaza, A; Zuanetti, G, 1985) |
| "In the MVP group, the following arrhythmias were induced: nonsustained polymorphic VT in 10, VF in three, and ventricular flutter in one." | 1.27 | The yield of programmed ventricular stimulation in mitral valve prolapse patients with ventricular arrhythmias. ( Gang, ES; Hamer, A; Mandel, WJ; Oseran, DS; Peter, T; Rosenthal, ME, 1985) |
| "Mexiletine 10 microM was found to be very effective against all three types of arrhythmias in all three groups." | 1.27 | Electrophysiological mechanisms for the antiarrhythmic action of mexiletine on digitalis-, reperfusion- and reoxygenation-induced arrhythmias. ( Amerini, S; Carbonin, P; Cerbai, E; Giotti, A; Mugelli, A; Pahor, M, 1985) |
| "In four children the first signs of arrhythmias were seen a short time after viral infection." | 1.26 | [Mexiletine in the treatment of ventricular arrhythmias (author's transl)]. ( Schlemmer, M; Wimmer, M, 1982) |
| "Mexiletine was used in 12 patients." | 1.26 | [Anti-arrhythmic effects of mexiletine]. ( Besse, P; Favreau, L; Ledain, L; Page, A, 1982) |
| " In 26 of the 32 patients optimum dosage for maximum beneficial effect appeared to be 200 mg 3 times daily." | 1.26 | [Treatment of rhythm disorders of ventricular origin with KO 1173 (Mexiletin) (author's transl)]. ( Esser, H; Kikis, D, 1977) |
| "In 9 cases, the ventricular premature beats were totally or almost totally abolished up to 20 to 100 min." | 1.26 | The efficacy of intravenous mexiletine on ventricular ectopic activity. ( Kulbertus, HE; Waleffe, A, 1977) |
| "Mexiletine appears to be an effective alternative to currently available antiarrhythmic agents." | 1.26 | Mexiletine in treatment of ventricular arrhythmias. A long-term follow-up. ( Hanson, A; Johansson, BW; Stavenow, L, 1979) |
| " The long therapeutic half-life of the drug allowed convenient dosage schedule and good compliance." | 1.26 | Mexiletine. Use in control of chronic drug-resistant ventricular arrhythmia. ( Abinader, EG; Cooper, M, 1979) |
| "Mexiletine (1." | 1.26 | [The effects of intravenous mexiletine on cardiac performance (author's transl)]. ( Chiariello, M; Condorelli, M; Ferro, G; Santinelli, V; Tari, MG, 1979) |
| " Mexitil--a potent class I antiarrhythmic drug--significantly reduced the incidence of ventricular arrhythmias at rest, normal physical activity and after ergometric loading during initial intravenous therapy followed by continuous oral administration over a three-week period at a daily dosage of 600 to 800 mg." | 1.26 | [The influence of mexiletin on ventricular arrhythmias during ergometric exercise (author's transl)]. ( Pozenel, H, 1977) |
| "These arrhythmias were thought to be caused by varicella myocarditis and were resistant to most common antiarrhythmic agents." | 1.26 | Varicella myocarditis presenting with unusual ventricular arrhythmias. ( Campbell, RW; Fiddler, GI; Godman, MJ; Pottage, A, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 240 (79.47) | 18.7374 |
| 1990's | 37 (12.25) | 18.2507 |
| 2000's | 6 (1.99) | 29.6817 |
| 2010's | 11 (3.64) | 24.3611 |
| 2020's | 8 (2.65) | 2.80 |
| Authors | Studies |
|---|---|
| Kumazawa, T | 2 |
| Harakawa, H | 1 |
| Obase, H | 1 |
| Oiji, Y | 1 |
| Nito, M | 1 |
| Kubo, K | 1 |
| Ishii, A | 1 |
| Tomioka, S | 1 |
| Yamada, Y | 1 |
| Hankovszky, OH | 1 |
| Hideg, K | 1 |
| Bódi, I | 1 |
| Frank, L | 1 |
| Vivier, D | 1 |
| Bennis, K | 1 |
| Lesage, F | 1 |
| Ducki, S | 1 |
| Wåström, M | 1 |
| Pfammatter, JP | 1 |
| Nakashima, R | 1 |
| Takase, S | 1 |
| Kai, K | 1 |
| Sakamoto, K | 1 |
| Tsutsui, H | 1 |
| van der Ree, MH | 1 |
| van Dussen, L | 1 |
| Rosenberg, N | 1 |
| Stolwijk, N | 1 |
| van den Berg, S | 1 |
| van der Wel, V | 1 |
| Jacobs, BAW | 1 |
| Wilde, AAM | 1 |
| Hollak, CEM | 1 |
| Postema, PG | 1 |
| Olleik, F | 1 |
| Kamareddine, MH | 1 |
| Spears, J | 1 |
| Tse, G | 1 |
| Liu, T | 1 |
| Yan, GX | 1 |
| Catalano, A | 2 |
| Franchini, C | 1 |
| Carocci, A | 2 |
| Vio, R | 1 |
| Zorzi, A | 1 |
| Corrado, D | 1 |
| Calore, C | 1 |
| Gutiérrez-Ballesteros, G | 1 |
| Bermúdez-Jiménez, FJ | 1 |
| Jiménez-Jáimez, J | 1 |
| Jæger, KH | 1 |
| Wall, S | 1 |
| Tveito, A | 1 |
| Varian, K | 1 |
| Tang, WHW | 1 |
| Frommeyer, G | 1 |
| Garthmann, J | 1 |
| Ellermann, C | 1 |
| Dechering, DG | 1 |
| Kochhäuser, S | 1 |
| Reinke, F | 1 |
| Köbe, J | 1 |
| Wasmer, K | 1 |
| Eckardt, L | 1 |
| Tunca Sahin, G | 1 |
| Ergul, Y | 1 |
| Minegaki, Y | 1 |
| Higashida, Y | 1 |
| Ogawa, M | 1 |
| Miyachi, Y | 1 |
| Fujii, H | 1 |
| Kabashima, K | 1 |
| Osadchii, OE | 1 |
| Iyer, V | 1 |
| Roman-Campos, D | 1 |
| Sampson, KJ | 1 |
| Kang, G | 1 |
| Fishman, GI | 1 |
| Kass, RS | 1 |
| Nguyen, CE | 1 |
| Campbell, C | 1 |
| Lee, SP | 1 |
| Kim, SH | 1 |
| Kim, TH | 1 |
| Sohn, JW | 1 |
| Shin, DH | 1 |
| Park, SS | 1 |
| Yoon, HJ | 1 |
| Gelzer, AR | 1 |
| Kraus, MS | 1 |
| Rishniw, M | 1 |
| Hemsley, SA | 1 |
| Moïse, NS | 2 |
| Meurs, KM | 1 |
| Spier, AW | 1 |
| Wright, NA | 1 |
| Atkins, CE | 1 |
| DeFrancesco, TC | 1 |
| Gordon, SG | 1 |
| Hamlin, RL | 1 |
| Keene, BW | 1 |
| Miller, MW | 1 |
| Valdivia, CR | 2 |
| Tester, DJ | 1 |
| Rok, BA | 1 |
| Porter, CB | 1 |
| Munger, TM | 1 |
| Jahangir, A | 1 |
| Makielski, JC | 2 |
| Ackerman, MJ | 1 |
| Plant, LD | 1 |
| Bowers, PN | 1 |
| Liu, Q | 1 |
| Morgan, T | 1 |
| Zhang, T | 2 |
| State, MW | 1 |
| Chen, W | 1 |
| Kittles, RA | 1 |
| Goldstein, SA | 1 |
| Tan, BH | 1 |
| Song, C | 1 |
| Tian, XL | 1 |
| Cheng, Y | 1 |
| Liao, ML | 1 |
| Yong, SL | 1 |
| Wang, QK | 1 |
| Sanna, GP | 2 |
| Opie, LH | 1 |
| Hoffmann, A | 2 |
| Follath, F | 3 |
| Burckhardt, D | 2 |
| Fossati, C | 1 |
| Giustiniani, S | 1 |
| Kipshidze, NN | 1 |
| Chapidze, GE | 1 |
| Dzhandzhgava, ShM | 1 |
| Ol'binskaia, LI | 1 |
| Iurina, MS | 1 |
| Litvitskiĭ, PF | 1 |
| Sandrikov, VA | 1 |
| Codecà, L | 2 |
| Gruppillo, P | 2 |
| Padovan, GC | 2 |
| Masoni, C | 2 |
| Masoni, A | 2 |
| Rolli, A | 2 |
| Bonatti, V | 2 |
| Finardi, A | 1 |
| Favaro, L | 1 |
| Botti, G | 2 |
| Bellocci, F | 1 |
| Ansalone, G | 1 |
| Scabbia, E | 1 |
| Santarelli, P | 1 |
| Lucente, M | 2 |
| Affinito, V | 1 |
| Loperfido, F | 1 |
| Zecchi, P | 1 |
| Zacà, F | 2 |
| Cremonesi, A | 1 |
| Pagliarani, PL | 1 |
| Guelfi, P | 1 |
| Bugiardini, R | 1 |
| Lasagna, I | 1 |
| Ghinelli, M | 2 |
| Luciani, G | 1 |
| Mehta, J | 1 |
| Conti, CR | 1 |
| Woosley, RL | 5 |
| Roden, DM | 4 |
| Duff, HJ | 5 |
| Oates, JA | 2 |
| Schlemmer, M | 2 |
| Wimmer, M | 2 |
| Ledain, L | 1 |
| Page, A | 1 |
| Favreau, L | 1 |
| Besse, P | 1 |
| Lüderitz, B | 4 |
| Richard, M | 1 |
| Touminet, MA | 1 |
| Revillon, L | 1 |
| Menozzi, C | 2 |
| Lolli, G | 2 |
| Monducci, I | 2 |
| Gheller, G | 1 |
| Brignole, M | 2 |
| Cattabiani, ML | 1 |
| Vergoni, W | 2 |
| Barone, A | 1 |
| Carmeliet, E | 1 |
| Wang, T | 1 |
| Stone, W | 1 |
| Siddoway, L | 1 |
| Thompson, K | 1 |
| Cerskus, I | 1 |
| Roden, D | 2 |
| Fenster, PE | 2 |
| Hanson, CD | 1 |
| Sgammini, HO | 1 |
| Evequoz, MC | 1 |
| Chuit, R | 1 |
| Atti, R | 1 |
| Santamarina, NO | 1 |
| Kuschnir, E | 1 |
| Singh, JB | 1 |
| Rasul, AM | 1 |
| Shah, A | 1 |
| Adams, E | 1 |
| Flessas, A | 1 |
| Kocot, SL | 1 |
| Dłuzniewski, M | 1 |
| Zalewski, A | 1 |
| Grochowicz, U | 1 |
| Chamiec, T | 1 |
| Walczak, F | 1 |
| Dorociak, A | 1 |
| Shanks, RG | 6 |
| Schoenfeld, MH | 1 |
| Whitford, E | 1 |
| McGovern, B | 1 |
| Garan, H | 2 |
| Ruskin, JN | 2 |
| Akhtar, M | 1 |
| Modlińska, J | 1 |
| Smyllie, HC | 1 |
| Doar, JW | 1 |
| Head, CD | 1 |
| Leggett, RJ | 1 |
| Halinen, MO | 1 |
| Pentikäinen, PJ | 1 |
| Helin, MJ | 1 |
| Rehnberg, S | 1 |
| Rosen, MR | 2 |
| Wit, AL | 1 |
| Manz, M | 1 |
| Steinbeck, G | 3 |
| Rossi, L | 1 |
| Mead, RH | 1 |
| Harrison, DC | 2 |
| Hellestrand, KJ | 1 |
| Berchtold-Kanz, E | 1 |
| Schwarz, G | 1 |
| Hust, M | 2 |
| Nitsche, K | 1 |
| Just, H | 3 |
| Heger, JJ | 1 |
| Prystowsky, EN | 1 |
| Zipes, DP | 3 |
| Pratt, CM | 1 |
| Luck, JC | 1 |
| Mann, DE | 1 |
| Wyndham, CR | 1 |
| Marzegalli, M | 1 |
| Bernasconi, M | 1 |
| Brambilla, G | 1 |
| Micheletti, T | 1 |
| Potenza, S | 1 |
| Regalia, F | 1 |
| Barbaresco, L | 1 |
| Bossi, M | 1 |
| Flaker, GC | 2 |
| Madigan, NP | 1 |
| Alpert, MA | 1 |
| Moser, SA | 1 |
| Stein, J | 3 |
| Podrid, P | 1 |
| Lown, B | 6 |
| Lotto, A | 1 |
| Finzi, A | 1 |
| Massari, FM | 1 |
| Pagnoni, F | 1 |
| Valentini, R | 1 |
| Ambrosini, F | 1 |
| Lo Masto, M | 1 |
| Ohashi, K | 1 |
| Ebihara, A | 1 |
| Hashimoto, T | 2 |
| Hosoda, S | 1 |
| Kondo, K | 1 |
| Oka, T | 1 |
| Kern, KB | 1 |
| Nitsch, J | 2 |
| Angermann, C | 1 |
| Jahrmärker, H | 1 |
| Ciraolo, O | 1 |
| Quartarone, M | 1 |
| Corica, F | 1 |
| D'Andrea Petrelli, L | 1 |
| Barbera, N | 1 |
| Ceruso, D | 1 |
| Rizzo, A | 1 |
| Sisto, F | 1 |
| Fiorilli, R | 1 |
| Lisanti, P | 1 |
| Tanaka, T | 2 |
| Kusumoto, M | 2 |
| Umemura, J | 2 |
| Miyazawa, Y | 2 |
| Suwa, J | 2 |
| Komatsu, Y | 2 |
| Mastropaolo, W | 1 |
| Holmes, DR | 1 |
| Osborn, MJ | 1 |
| Rooke, J | 1 |
| Moyer, TP | 1 |
| Bigger, JT | 1 |
| Podrid, PJ | 8 |
| Lampert, S | 3 |
| Hirsowitz, G | 1 |
| Johansson, BW | 2 |
| Stavenow, L | 2 |
| Hanson, A | 2 |
| Schütz, E | 1 |
| White, R | 1 |
| Upward, JW | 1 |
| Holt, DW | 5 |
| Jackson, G | 3 |
| Meoli, P | 1 |
| Rovelli, F | 1 |
| Benchimol, A | 1 |
| Desser, KB | 1 |
| Singh, BN | 3 |
| Cho, YW | 1 |
| Kuemmerle, HP | 1 |
| Nademanee, K | 1 |
| Flouvat, B | 1 |
| Witkowska, M | 1 |
| Hashimoto, K | 3 |
| Shibuya, T | 1 |
| Satoh, H | 1 |
| Imai, S | 1 |
| Primm, RK | 1 |
| Chadwick, DE | 1 |
| Campbell, RW | 11 |
| Disertori, M | 1 |
| Vergara, G | 1 |
| Inama, G | 1 |
| Guarnerio, M | 1 |
| Furlanello, F | 1 |
| Pachecus, A | 1 |
| Santoni, Y | 1 |
| Fornaris, M | 1 |
| Magnan, S | 1 |
| Aubert, C | 1 |
| Ragon, A | 1 |
| Cano, JP | 1 |
| Henrard, L | 1 |
| Carlier, J | 1 |
| Winkle, RA | 2 |
| Kulbertus, HE | 2 |
| Van Durme, JP | 1 |
| Boyle, DM | 3 |
| Perrenoud, JJ | 1 |
| Merx, W | 2 |
| Franken, G | 1 |
| Brunner, H | 2 |
| Effert, S | 1 |
| Henning, B | 2 |
| Trimarco, B | 2 |
| Volpe, M | 2 |
| Ricciardelli, B | 2 |
| Sacca', L | 1 |
| De Luca, N | 2 |
| Rengo, F | 3 |
| Condorelli, M | 4 |
| Meinertz, T | 3 |
| Kasper, W | 1 |
| Stengel, E | 1 |
| Waldecker, B | 1 |
| Löllgen, H | 1 |
| Jähnchen, E | 1 |
| Bechtold, H | 1 |
| Just, J | 1 |
| Pitt, B | 1 |
| Bury, RW | 1 |
| Hale, G | 1 |
| Higginbotham, M | 1 |
| Mashford, ML | 1 |
| Zuidland, P | 1 |
| Trenckmann, H | 1 |
| Neugebauer, A | 1 |
| Krosse, B | 1 |
| Bell, JA | 1 |
| Thomas, JM | 1 |
| Isaacson, JR | 1 |
| Snell, NJ | 1 |
| Munuswamy, K | 1 |
| Vozeh, S | 1 |
| Katz, G | 1 |
| Steiner, V | 1 |
| Böcker, K | 1 |
| Köhler, E | 1 |
| Seipel, L | 3 |
| Loogen, F | 1 |
| González Zuelgaray, J | 1 |
| Nieves, E | 1 |
| Fernández, R | 1 |
| Posse, RA | 1 |
| Shakibi, JG | 1 |
| Moezzi, B | 1 |
| Guiducci, U | 1 |
| Bertulla, A | 1 |
| Pristautz, H | 1 |
| Biffl, H | 1 |
| Leitner, W | 1 |
| Parsché, P | 1 |
| Schmid, P | 1 |
| Tomassetti, V | 1 |
| Fontana, F | 1 |
| Masi, M | 1 |
| Mezzetti, A | 1 |
| Poggiopollini, G | 1 |
| Cuppini, A | 1 |
| Cuccurullo, F | 1 |
| Dimitrov, D | 1 |
| Dzhurdzhev, A | 1 |
| Batalov, Z | 1 |
| D'Ascia, C | 1 |
| Bonaduce, D | 2 |
| Cady, WJ | 1 |
| Wilson, CS | 1 |
| Chambers, WA | 1 |
| Miles, RR | 1 |
| Holcslaw, TL | 1 |
| Forker, AD | 1 |
| Chapman, C | 1 |
| Kinney, C | 1 |
| McIlmoyle, EL | 1 |
| Salathia, K | 1 |
| Joseph, SP | 2 |
| Kána, A | 1 |
| Florcíková, L | 1 |
| Jurecková, A | 1 |
| Klabusay, L | 1 |
| Simícek, J | 1 |
| Tomecková, A | 1 |
| Malcolm, ID | 1 |
| Stubington, D | 1 |
| Gibbons, JE | 1 |
| Härtel, GU | 1 |
| DiMarco, JP | 1 |
| Cernusková, L | 1 |
| Benes, L | 1 |
| Csöllei, J | 1 |
| Tumová, I | 1 |
| Svec, P | 1 |
| Komori, S | 2 |
| Sawanobori, T | 1 |
| Tamura, K | 2 |
| Kane, KA | 2 |
| Parratt, JR | 1 |
| Oledzka, K | 1 |
| Filczewski, M | 1 |
| Kosmala, M | 1 |
| Miłobedzka, J | 1 |
| Sadanaga, T | 2 |
| Ogawa, S | 2 |
| Okada, Y | 2 |
| Tsutsumi, N | 1 |
| Iwanaga, S | 1 |
| Yoshikawa, T | 1 |
| Akaishi, M | 1 |
| Handa, S | 2 |
| Saikawa, T | 1 |
| Ito, M | 1 |
| Nakagawa, M | 2 |
| Shimoyama, N | 1 |
| Hara, M | 1 |
| Yonemochi, H | 1 |
| Maeda, T | 1 |
| Inoue, T | 1 |
| Takaki, R | 1 |
| Arita, M | 1 |
| Mondillo, S | 1 |
| Faglia, S | 1 |
| D'Aprile, N | 1 |
| Mangiacotti, L | 1 |
| Campolo, MA | 1 |
| Agricola, E | 1 |
| Palazzuoli, V | 1 |
| Murakami, M | 1 |
| Kinukawa, M | 1 |
| Kanazawa, T | 1 |
| Maruyama, K | 1 |
| Miyagi, M | 1 |
| Miyata, H | 1 |
| Ujiie, A | 1 |
| Weissenburger, J | 1 |
| Chezalviel-Guilbert, F | 1 |
| Davy, JM | 1 |
| Uenaka, K | 1 |
| Koue, T | 1 |
| Iwai, T | 1 |
| Shibakawa, M | 1 |
| Ueno, K | 2 |
| Xue, YX | 1 |
| Arita, J | 1 |
| Aye, NN | 1 |
| Lanchote, VL | 1 |
| Cesarino, EJ | 1 |
| Santos, VJ | 1 |
| Mere Júnior, Y | 1 |
| Santos, SR | 1 |
| Yonezawa, E | 1 |
| Matsumoto, K | 1 |
| Tachibana, M | 1 |
| Hashimoto, H | 1 |
| Komamura, K | 1 |
| Kamakura, S | 1 |
| Miyatake, K | 1 |
| Tanaka, K | 1 |
| Julian, DG | 9 |
| Carson, IW | 1 |
| Lyons, SM | 1 |
| Dolder, MA | 2 |
| Prescott, LF | 4 |
| Talbot, RG | 7 |
| Murray, A | 5 |
| Campbell, NP | 4 |
| Chaturvedi, NC | 1 |
| Kelly, JG | 3 |
| Strong, JE | 1 |
| Adgey, AA | 4 |
| Esser, H | 2 |
| Kikis, D | 2 |
| Waleffe, A | 1 |
| Steinbach, K | 1 |
| Glogar, D | 1 |
| Weber, H | 1 |
| Kinast, H | 1 |
| Joskowicz, G | 1 |
| Kaindl, F | 1 |
| Mazur, NA | 2 |
| Liakishev, AA | 1 |
| Podrid, FD | 1 |
| Piotrovskiĭ, VK | 1 |
| Coumel, P | 1 |
| Krikler, D | 1 |
| Wellens, HJ | 1 |
| Chiariello, M | 2 |
| Ferro, G | 2 |
| Santinelli, V | 2 |
| Tari, MG | 2 |
| Jewitt, DE | 1 |
| McComish, M | 2 |
| Achuff, SC | 1 |
| Pottage, A | 3 |
| Prescott, L | 2 |
| Koch, G | 1 |
| Lindström, B | 1 |
| Kühn, P | 1 |
| Pozenel, H | 2 |
| Dolder, M | 3 |
| Prescott, LE | 2 |
| Myburgh, DP | 1 |
| Goldman, AP | 1 |
| Chew, CY | 1 |
| Collett, J | 1 |
| Danilo, P | 1 |
| Abinader, EG | 1 |
| Cooper, M | 1 |
| Harper, RW | 2 |
| Olsson, SB | 2 |
| Varnauskas, E | 1 |
| Kujat, R | 1 |
| Dittrich, H | 1 |
| Pantridge, JF | 2 |
| Novo Valledor, L | 1 |
| Eizaguirre Pérez, AJ | 1 |
| Haap, K | 1 |
| Antoni, H | 1 |
| Anderson, JL | 1 |
| Meffin, PJ | 1 |
| Dienstl, F | 1 |
| Koller, H | 1 |
| Prager, H | 1 |
| Sterz, H | 1 |
| Troup, PJ | 1 |
| Breithardt, G | 1 |
| Schoerner, U | 1 |
| Härtel, H | 1 |
| Jewitt, D | 1 |
| Nimmo, J | 1 |
| Barber, JM | 1 |
| Ferguson, RW | 1 |
| Allen, JD | 1 |
| James, RG | 1 |
| Zaidi, SA | 1 |
| Fiddler, GI | 1 |
| Godman, MJ | 1 |
| Lellouche, D | 1 |
| Bougherbal, R | 1 |
| Takanaka, C | 1 |
| Nonokawa, M | 1 |
| Machii, T | 1 |
| Lee, S | 1 |
| Kato, H | 1 |
| Haruna, M | 1 |
| Yabe, S | 1 |
| Delbressine, L | 1 |
| Harris, N | 1 |
| Muir, AW | 1 |
| Winslow, E | 1 |
| Brakhmann, I | 1 |
| Shmitt, K | 1 |
| Baĭer, T | 1 |
| Valdeker, B | 1 |
| Khilbel, T | 1 |
| Kiubler, V | 1 |
| He, ZS | 1 |
| Kume, M | 1 |
| Kashimoto, S | 1 |
| Mitchell, LB | 1 |
| Wyse, DG | 1 |
| Gillis, AM | 1 |
| Sheldon, RS | 1 |
| Zang, Y | 1 |
| Yorikane, R | 1 |
| Mizuno, H | 1 |
| Itoh, Y | 1 |
| Koike, H | 1 |
| Miyake, S | 1 |
| Shiga, H | 1 |
| Kumakura, S | 1 |
| Fukami, M | 1 |
| Shimoji, Y | 1 |
| Dai, DZ | 1 |
| Rong, P | 1 |
| Huang, J | 1 |
| Liu, J | 1 |
| Cheng, JH | 1 |
| Chen, YH | 1 |
| Qiu, YT | 1 |
| Huang, WL | 1 |
| Peng, SX | 1 |
| Kikuchi, K | 1 |
| Tsunoda, T | 1 |
| Tagami, H | 1 |
| Kowey, PR | 1 |
| Frishman, WH | 1 |
| Arnold, RJ | 1 |
| Kaniecki, DJ | 1 |
| Beck, JR | 1 |
| Beshansky, JR | 1 |
| Shi, HM | 1 |
| Dai, RH | 1 |
| Wang, SY | 1 |
| Tanabe, T | 3 |
| Suzuki, M | 1 |
| Kobayashi, A | 1 |
| Yamazaki, N | 1 |
| Kobayashi, T | 1 |
| Watanabe, T | 1 |
| Ito, T | 1 |
| Ogawa, K | 1 |
| Giardina, EG | 1 |
| Wechsler, ME | 1 |
| Manolis, AS | 1 |
| Deering, TF | 1 |
| Cameron, J | 1 |
| Estes, NA | 1 |
| Conorev, EA | 1 |
| Rudnev, DV | 2 |
| Conorev, LA | 1 |
| Polumiskov, VY | 1 |
| Golikov, AP | 2 |
| Monk, JP | 1 |
| Brogden, RN | 1 |
| Bombardini, T | 1 |
| De Collibus, C | 1 |
| Zaccaria, O | 1 |
| Steffanon, L | 1 |
| Azzolini, U | 1 |
| Valentini, P | 1 |
| Puddu, P | 1 |
| Kerin, NZ | 1 |
| Aragon, E | 1 |
| Marinescu, G | 1 |
| Faitel, K | 1 |
| Frumin, H | 1 |
| Rubenfire, M | 1 |
| Uchida, H | 1 |
| Ozawa, E | 1 |
| Watanabe, Y | 1 |
| Takarada, A | 1 |
| Yokota, Y | 1 |
| Fukuzaki, H | 1 |
| Horowitz, LN | 2 |
| Greenspan, AM | 2 |
| Spielman, SR | 2 |
| Frye, SJ | 1 |
| Yacone, LA | 1 |
| Lowenthal, DT | 1 |
| Accettura, D | 1 |
| De Toma, L | 1 |
| Lagioia, R | 1 |
| Mastropasqua, F | 1 |
| Mangini, SG | 1 |
| Scrutinio, D | 1 |
| Rizzon, P | 2 |
| Vitale, P | 1 |
| Agretto, A | 1 |
| Iarussi, D | 1 |
| Perna, B | 1 |
| Romano, A | 1 |
| Casale, D | 1 |
| Porreca, GP | 1 |
| Chaudron, JM | 1 |
| Luwaert, RJ | 1 |
| Harron, DW | 2 |
| Zehender, M | 2 |
| Geibel, A | 2 |
| Hohnloser, S | 2 |
| Abdalla, A | 1 |
| Patt, MV | 1 |
| Grossbard, CL | 1 |
| Graboys, TB | 1 |
| Poggesi, L | 1 |
| Scarti, L | 1 |
| Ieri, A | 1 |
| Lanzetta, T | 1 |
| Grazzini, M | 1 |
| Del Bene, P | 1 |
| Masini, G | 1 |
| Del Citerna, F | 1 |
| Carnovali, M | 1 |
| Masotti, G | 1 |
| Liem, LB | 1 |
| Kates, RE | 1 |
| Skluth, H | 1 |
| Grauer, K | 1 |
| Gums, J | 1 |
| Murray, KT | 1 |
| Barbey, JT | 1 |
| Kopelman, HA | 1 |
| Siddoway, LA | 1 |
| Echt, DS | 1 |
| Snyder, DW | 1 |
| Aguglia, F | 1 |
| Gnecchi, M | 1 |
| De Marzio, P | 1 |
| Yoshikawa, H | 2 |
| Tagawa, R | 1 |
| Furuya, H | 2 |
| Ide, M | 1 |
| Goto, Y | 2 |
| Evers, J | 1 |
| Messer, W | 1 |
| Aboudan, F | 1 |
| Finke, K | 1 |
| Skwarski, K | 2 |
| Sliwiński, P | 2 |
| Górecka, D | 1 |
| Zieliński, J | 2 |
| Liusov, VA | 1 |
| Dudaev, VA | 1 |
| Borodkin, VV | 1 |
| Rudakov, AV | 1 |
| Fracalossi, C | 1 |
| Ziacchi, V | 1 |
| Farisè, F | 1 |
| Rossi, A | 1 |
| Marino, A | 1 |
| Lomanto, B | 1 |
| Moretti, L | 1 |
| Omori, I | 1 |
| Inoue, D | 1 |
| Shirayama, T | 1 |
| Azuma, A | 1 |
| Sugihara, H | 1 |
| Furukawa, K | 1 |
| Asayama, J | 1 |
| Katsume, H | 1 |
| Somberg, J | 1 |
| Haggman, DL | 1 |
| Maloney, JD | 1 |
| Morant, VA | 1 |
| Castle, LW | 1 |
| King-Rankine, M | 1 |
| Goormastic, M | 1 |
| Kim, SG | 1 |
| Mercando, AD | 1 |
| Tam, S | 1 |
| Fisher, JD | 1 |
| Nora, MO | 1 |
| Chandrasekaran, K | 1 |
| Hammill, SC | 1 |
| Reeder, GS | 1 |
| Kessler, KM | 1 |
| Interian, A | 1 |
| Cox, M | 1 |
| Topaz, O | 1 |
| De Marchena, EJ | 1 |
| Myerburg, RJ | 1 |
| Kościńska, M | 1 |
| Hession, M | 1 |
| Blum, R | 1 |
| Nestico, PF | 2 |
| Morganroth, J | 3 |
| Huang, SK | 1 |
| Marcus, FI | 1 |
| Moak, JP | 2 |
| Smith, RT | 2 |
| Garson, A | 2 |
| Di Biase, M | 1 |
| Favale, S | 1 |
| Visani, L | 1 |
| Priori, SG | 1 |
| Bonazzi, O | 1 |
| Facchini, M | 1 |
| Varisco, T | 1 |
| Schwartz, PJ | 3 |
| Slater, W | 1 |
| Lanza, GA | 1 |
| Tamburi, S | 1 |
| Mondello Malvestiti, FM | 1 |
| Rebuzzi, AG | 1 |
| Treese, N | 1 |
| Denniss, AR | 1 |
| Ross, DL | 1 |
| Cody, DV | 1 |
| Russell, PA | 1 |
| Young, AA | 1 |
| Richards, DA | 1 |
| Uther, JB | 1 |
| Garimoldi, M | 1 |
| Pirastu, A | 1 |
| Barbanotti, G | 1 |
| Sghirinzetti, M | 1 |
| Catalano, M | 1 |
| Castelfranco, M | 1 |
| Amerini, S | 2 |
| Bernabei, R | 1 |
| Carbonin, P | 2 |
| Cerbai, E | 2 |
| Mugelli, A | 2 |
| Pahor, M | 2 |
| Gregg, AR | 1 |
| Tomich, PG | 1 |
| Endou, K | 1 |
| Yamamoto, H | 1 |
| Sato, T | 1 |
| Fazio, S | 1 |
| Villari, B | 1 |
| Petitto, M | 1 |
| Santomauro, M | 1 |
| Iacono, C | 1 |
| Celentano, A | 1 |
| de Divitiis, O | 1 |
| Varró, A | 1 |
| Rabloczky, G | 1 |
| Jaszlits, L | 1 |
| Kürthy, M | 1 |
| Zubovics, Z | 1 |
| Toldy, L | 1 |
| Sakai, K | 1 |
| Yamazaki, T | 1 |
| Takagi, M | 1 |
| Lownes, HE | 1 |
| Ives, TJ | 1 |
| Joeres, R | 1 |
| Klinker, H | 1 |
| Heusler, H | 1 |
| Epping, J | 1 |
| Richter, E | 1 |
| Peyrieux, JC | 1 |
| Boissel, JP | 1 |
| Leizorovicz, A | 1 |
| Kuno, T | 1 |
| Takahashi, S | 1 |
| Hibiya, K | 1 |
| Shimada, A | 1 |
| Nagura, Y | 1 |
| Takeuchi, M | 1 |
| Hatano, M | 1 |
| Vanoli, E | 2 |
| Purcaro, A | 1 |
| Massacci, C | 1 |
| Curzi, G | 1 |
| Pigini, G | 1 |
| Costantini, C | 1 |
| Bilancini, A | 1 |
| Blandini, A | 1 |
| Pepper, GA | 1 |
| Lui, HK | 1 |
| Harris, FJ | 1 |
| Chan, MC | 1 |
| Lee, G | 1 |
| Mason, DT | 1 |
| Ferrara, N | 1 |
| Abete, P | 1 |
| Longobardi, G | 1 |
| Leosco, D | 1 |
| Canonico, V | 1 |
| Morgano, G | 1 |
| Klein, AL | 1 |
| Sami, MH | 1 |
| Smolenskiĭ, VS | 1 |
| Fomina, IG | 1 |
| Iankin, VV | 1 |
| Kolpakov, EV | 1 |
| Morgunov, NB | 1 |
| Jezek, L | 1 |
| Urbánková, G | 1 |
| Gasparík, J | 1 |
| Hudcovicová, E | 1 |
| Nosál, R | 1 |
| Hesek, D | 1 |
| Rybár, A | 1 |
| Mahrla, Z | 1 |
| Alamercery, Y | 1 |
| Wilkins, P | 1 |
| Karrison, T | 1 |
| Haedo, AH | 1 |
| Chiale, PA | 1 |
| Bandieri, JD | 1 |
| Lázzari, JO | 1 |
| Elizari, MV | 1 |
| Rosenbaum, MB | 1 |
| Zaza, A | 1 |
| Zuanetti, G | 1 |
| Sebbah, J | 1 |
| Khemache, A | 1 |
| Gryman, R | 1 |
| Farinotti, R | 1 |
| Guérot, C | 1 |
| Valère, PE | 1 |
| Brezina, M | 1 |
| Lillie, C | 1 |
| Kobinger, W | 1 |
| Rae, AP | 1 |
| Sokoloff, NM | 1 |
| Webb, CR | 1 |
| Rutledge, JC | 1 |
| Harris, F | 1 |
| Amsterdam, EA | 1 |
| Paciaroni, E | 1 |
| Ferroni, C | 1 |
| Marini, M | 1 |
| Campanari, G | 1 |
| Kitagawa, H | 1 |
| Takeda, F | 1 |
| Kohei, H | 1 |
| Rosenthal, ME | 1 |
| Hamer, A | 1 |
| Gang, ES | 1 |
| Oseran, DS | 1 |
| Mandel, WJ | 1 |
| Peter, T | 1 |
| Giotti, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042] | 27 participants (Actual) | Interventional | 2012-05-31 | Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.) | |||
| Short Term Renal Outcomes Among Post Liver Transplantation Patients at Assiut University[NCT06123260] | 50 participants (Anticipated) | Observational [Patient Registry] | 2023-12-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 7 |
Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 12 |
Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 7 |
| Antiarrhythmic Medication | 10 |
Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 11 |
| Antiarrhythmic Medication | 14 |
Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 6 |
| Antiarrhythmic Medication | 13 |
Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Catheter Ablation | 5 |
| Antiarrhythmic Medication | 1 |
Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months
| Intervention | Days (Mean) |
|---|---|
| Catheter Ablation | 70.1 |
| Antiarrhythmic Medication | 78.7 |
40 reviews available for mexiletine and Arrhythmia
| Article | Year |
|---|---|
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
Topics: Arrhythmias, Cardiac; Depression; Epilepsy; Humans; Inflammation; Models, Molecular; Molecular Struc | 2016 |
Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Child; Child, Preschool; Electroca | 2022 |
Mexiletine: Antiarrhythmic mechanisms, emerging clinical applications and mortality.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Long QT Syndrome; Mexiletine; Myocardium | 2023 |
Voltage-Gated Sodium Channel Blockers: Synthesis of Mexiletine Analogues and Homologues.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Mexiletine; Sodium Channel Blockers; Voltage-G | 2021 |
Therapeutic Strategies Targeting Inherited Cardiomyopathies.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cardiomyopathies; Diflunisal; Geneti | 2017 |
Antiarrhythmic Mexiletine: A Review on Synthetic Routes to Racemic and Homochiral Mexiletine and its Enantioseparation.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chromatography, High Pressure Liquid; Diabetic Nephrop | 2016 |
[Therapy of cardiac arrhythmias].
Topics: Adrenergic beta-Antagonists; Arrhythmias, Cardiac; Digitalis Glycosides; Electric Countershock; Elec | 1984 |
Mechanisms of arrhythmias and of antiarrythmic activity, with special reference to mexiletine.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Dogs; Guinea Pigs | 1980 |
Pharmacology, electrophysiology, and pharmacokinetics of mexiletine.
Topics: Absorption; Animals; Arrhythmias, Cardiac; Drug Combinations; Drug Evaluation; Electrophysiology; Hu | 1984 |
Hemodynamic effects of mexiletine.
Topics: Animals; Arrhythmias, Cardiac; Bradycardia; Coronary Disease; Hemodynamics; Humans; Male; Mexiletine | 1984 |
Oral mexiletine in the treatment of refractory ventricular arrhythmias: the role of electrophysiologic techniques.
Topics: Administration, Oral; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrophysiology; Heart; Huma | 1984 |
Practical considerations in the treatment of ventricular arrhythmias with mexiletine.
Topics: Adult; Aged; Animals; Arrhythmias, Cardiac; Dogs; Electrocardiography; Gastrointestinal Diseases; Hu | 1984 |
[Mexitil in the treatment of arrhythmia].
Topics: Administration, Oral; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Humans; Injections, In | 1984 |
Electropharmacology of antiarrhythmic drugs.
Topics: Action Potentials; Amiodarone; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disopyramide | 1983 |
Therapy with investigational antiarrhythmic drugs.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Encainide; Fl | 1984 |
Comparison of the efficacy of newly developed antiarrhythmic drugs in the treatment of ventricular tachyarrhythmias.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Coronary Disease; Encaini | 1984 |
Investigational antiarrhythmic drugs for the treatment of ventricular rhythm disturbances.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Encainide; Flecainide | 1984 |
[Clinical pharmacology of anti-arrhythymia agents. II. Lignocaine, mexiletine, tocainide, phenytoin].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Kinetics; Lidocaine; Mexiletine; Tocainide | 1981 |
Clinical antiarrhythmic efficacy of mexiletine: a review.
Topics: Administration, Oral; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Heart Con | 1980 |
[Utilization of anti-arrhythmic drugs].
Topics: Action Potentials; Ajmaline; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Digital | 1980 |
Sudden cardiac death: role of left ventricular dysfunction.
Topics: Arrhythmias, Cardiac; Coronary Disease; Death, Sudden; Electrocardiography; Heart Ventricles; Humans | 1982 |
Cardiac arrhythmias - a short review.
Topics: Adrenergic beta-Agonists; Arrhythmias, Cardiac; Digitalis Glycosides; Electric Countershock; Electro | 1976 |
Anti-arrhythmic drugs.
Topics: Adrenergic beta-Antagonists; Anesthetics; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dis | 1979 |
Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.
Topics: Arrhythmias, Cardiac; Electrophysiology; Hemodynamics; Humans; Intestinal Absorption; Kinetics; Mexi | 1979 |
Mexiletine/quinidine combination therapy: electrophysiologic correlates of anti-arrhythmic efficacy.
Topics: Animals; Arrhythmias, Cardiac; Drug Therapy, Combination; Electrophysiology; Heart; Humans; Mexileti | 1991 |
Comparative cost-effectiveness analysis of quinidine, procainamide and mexiletine.
Topics: Ambulatory Care; Arrhythmias, Cardiac; Cost-Benefit Analysis; Costs and Cost Analysis; Decision Maki | 1991 |
Mexiletine: pharmacology and therapeutic use.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Therapy, Combination; Hemodynamics; Humans; Mexil | 1990 |
Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Electrophysiology; Heart Conduction System; Humans; Mexiletine | 1990 |
The role of antiarrhythmic drugs in prevention of sudden cardiac death.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Cardiac Comple | 1985 |
Update: cardiac antiarrhythmic drugs.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Encainide; Fl | 1989 |
Ventricular arrhythmias. An assessment of newer therapeutic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Humans; Lidocaine; Mexiletine; | 1989 |
Class IB antiarrhythmic drugs: tocainide, mexiletine, and moricizine.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Lidocaine; Mexiletine; Moricizine; Phenothiazi | 1989 |
Antiarrhythmic drug therapy. Recent advances and current status.
Topics: Adrenergic beta-Antagonists; Ajmaline; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrh | 1985 |
Cardiac arrhythmias in the elderly: antiarrhythmic drug treatment.
Topics: Aged; Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Compounds; Digox | 1986 |
Antiarrhythmic drug therapy of ventricular arrhythmias.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bretylium Tosylate; Disopyramide; Flecaini | 1986 |
Antiarrhythmic agents for chronic ventricular arrhythmias.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Encainide; Flecain | 1987 |
Class 1B agents lidocaine, mexiletine, tocainide, phenytoin.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Lidocaine; Mexiletine; Phenytoin; Tocainide | 1987 |
Mexiletine.
Topics: Arrhythmias, Cardiac; Humans; Mexiletine; Myocardial Infarction | 1987 |
Tocainide and mexiletine. Orally effective lidocaine analogues.
Topics: Administration, Oral; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Kinetics; Lidocaine; Mex | 1985 |
Antiarrhythmic drug therapy (Part 2). Benefits and hazards.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Encainide; Fl | 1985 |
70 trials available for mexiletine and Arrhythmia
| Article | Year |
|---|---|
Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German shepherd dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cross-Over Studies; Dog Diseases; Dogs; Drug | 2010 |
Comparison of the effects of four antiarrhythmic treatments for familial ventricular arrhythmias in Boxers.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Dog Diseases; Dogs; Drug Therapy, C | 2002 |
[Clinical study of the anti-arrhythmia preparation, mexitil].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Tr | 1980 |
[Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias].
Topics: Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Female; Heart Ventricles; Humans; Lidocain | 1981 |
Mexiletine, a new antiarrhythmic agent, for treatment of premature ventricular complexes.
Topics: Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as Topic; Diarrhea; Double | 1982 |
Selection of an antiarrhythmic drug for a sudden-death-prevention trial.
Topics: Acecainide; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneac | 1982 |
International mexiletine and placebo antiarrhythmic coronary trial: I. Report on arrhythmia and other findings. Impact Research Group.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as Topic; Delayed-A | 1984 |
Mexiletine and quinidine in ventricular ectopy.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Electrocardiograph | 1983 |
[Treatment of arrhythmias with high risk of sudden death in chronic Chagas' cardiopathy with oral mexiletine. Evaluation with 24-hour ambulatory electrocardiographic monitoring (Holter)].
Topics: Adult; Aged; Arrhythmias, Cardiac; Chagas Cardiomyopathy; Clinical Trials as Topic; Death, Sudden; E | 1983 |
Efficacy of mexiletine in chronic ventricular arrhythmias compared with quinidine: a single-blind, randomized trial.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Female; Heart Ventricles; Humans; Male; | 1984 |
[Mexitil in the treatment of ventricular arrhythmia (personal experiences)].
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Heart Ventricles; Humans; Mexiletine; M | 1983 |
[Mexiletine in the treatment of arrhythmia].
Topics: Arrhythmias, Cardiac; Biological Availability; Clinical Trials as Topic; Humans; Kinetics; Mexiletin | 1983 |
Hemodynamic effects of mexiletine.
Topics: Animals; Arrhythmias, Cardiac; Bradycardia; Coronary Disease; Hemodynamics; Humans; Male; Mexiletine | 1984 |
Oral mexiletine in the treatment of refractory ventricular arrhythmias: the role of electrophysiologic techniques.
Topics: Administration, Oral; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrophysiology; Heart; Huma | 1984 |
A trial of intravenous and oral mexiletine in acute myocardial infarction.
Topics: Administration, Oral; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Infusions, Parenteral; | 1984 |
Antiarrhythmic efficacy of combined intravenous and oral mexiletine in acute myocardial infarction. A double blind placebo-controlled study.
Topics: Adult; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Fem | 1984 |
[Long-term drug therapy in ventricular cardiac arrhythmias. Is an improvement of the prognosis possible?].
Topics: Adult; Aged; Amiodarone; Aprindine; Arrhythmias, Cardiac; Disopyramide; Humans; Long-Term Care; Mexi | 1983 |
[Comparative evaluation of mexiletine and propafenone by dynamic electrocardiography].
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Electrocardiography; Female; H | 1984 |
[Comparative studies on the cardiodepressant effect of disopyramide, mexiletine and propafenon].
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Echocardiography; Female; Heart R | 1983 |
[Clinical study evaluated by Holter monitoring and by mexiletine serum levels in ventricular arrhythmias].
Topics: Administration, Oral; Adolescent; Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Elect | 1982 |
Clinical antiarrhythmic efficacy of mexiletine: a review.
Topics: Administration, Oral; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Heart Con | 1980 |
Evaluation of the antiarrhythmic efficacy of mexiletine in patients with chronic ventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Atenolol; Chronic Disease; Clinical Trials as Topic; Disopyramide; Double-Blin | 1980 |
Mexiletine in clinical practice.
Topics: Acute Disease; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Lidoc | 1980 |
[Mexiletin for treatment of ventricular ectopic rhythm in patients with acute myocardial infarction (author's transl)].
Topics: Acute Disease; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Female; Heart Ventricles; Human | 1980 |
Disopyramide and mexiletine: which is the agent of choice in the long term-oral treatment of lidocaine-responsive arrhythmias? Efficacy comparison in a randomized trial.
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyramide; Electrocardiography; Humans; Lidocaine | 1980 |
Comparison of the antiarrhythmic activity of mexiletine and lorcainide on ventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzeneacetamides; Clinical Trials as Top | 1982 |
Mexiletine vs. lignocaine in the management of ventricular arrhythmias after open-heart surgery.
Topics: Arrhythmias, Cardiac; Cardiac Surgical Procedures; Clinical Trials as Topic; Female; Heart Ventricle | 1982 |
[Effect of kidney, liver or heart insufficiency on blood mexiletine levels].
Topics: Arrhythmias, Cardiac; Biological Availability; Chromatography, Gas; Chronic Disease; Heart Failure; | 1982 |
[Treatment of ventricular arrhythmias with mexiletine].
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Biological Availability; Clinical Trials as | 1982 |
A trial of prophylactic mexiletine in home coronary care.
Topics: Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Fema | 1982 |
A comparison of mexiletine and a slow release formulation of mexiletine in patients admitted to a coronary care unit [proceedings].
Topics: Arrhythmias, Cardiac; Coronary Disease; Delayed-Action Preparations; Humans; Mexiletine; Propylamine | 1980 |
[Therapy of arrhythmia induced by myocardial ischemia. Association of L-carnitine, propafenone and mexiletine].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Carnitine; Drug Sy | 1995 |
Enantioselectivity in the metabolism of mexiletine by conjugation in female patients with the arrhythmic form of chronic Chagas' heart disease.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Area Under Curve; Arrhythmias, Cardiac; Biotransformation; Chag | 1999 |
Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction.
Topics: Administration, Oral; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Drug Evaluation; Humans; | 1975 |
Long-term treatment of ventricular arrhythmias with oral mexiletine.
Topics: Administration, Oral; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as T | 1976 |
[Clinical value of computer-assisted arrhythmia analysis].
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as Topic; Computers | 1978 |
Ventricular arrhythmias after acute myocardial infarction treated with procainamide or mexiletine.
Topics: Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Male; Mexiletine; Myocardial Infarctio | 1977 |
Comparative anti-arrhythmic efficacy of mexiletine, procainamide and tolamolol in patients with symptomatic ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Female; Heart Ventricles; Humans; Male; | 1977 |
Mexiletine in the prevention of ventricular arrhythmias in acute myocardial infarction.
Topics: Administration, Oral; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Female; Humans; Male; Me | 1977 |
Efficacy of oral mexiletine in the prevention of exercise-induced ventricular ectopic activity.
Topics: Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Fe | 1978 |
[Four year experience with mexiletine].
Topics: Adult; Arrhythmias, Cardiac; Clinical Trials as Topic; Female; Hemodynamics; Humans; Male; Mexiletin | 1978 |
[The effect of mexiletine, ajmaline and aprindine on ventricular arrhythmias].
Topics: Aged; Ajmaline; Aprindine; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiography; Fema | 1978 |
[Short-and long-term therapy with Mexitil].
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiography; Female; Humans; Ma | 1978 |
[Treatment of ventricular arrhythmias after acute myocardial infarct with procaine amide and mexiletine].
Topics: Adult; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Hea | 1978 |
The anti-arrhythmic efficacy of perhexiline maleate, disopyramide and mexiletine in ventricular ectopic activity.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Disopyramide; Heart V | 1978 |
Side-effects of mexiletene.
Topics: Arrhythmias, Cardiac; Humans; Lidocaine; Mexiletine; Propylamines | 1978 |
Ambulatory monitoring in the controlled assessment of anti-arrhythmic drug therapy.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiography; Female; Humans; Ma | 1976 |
[Frequency and prevention of ventricular arrhythmias after acute myocardial infarct].
Topics: Arrhythmias, Cardiac; Humans; Male; Mexiletine; Myocardial Infarction | 1976 |
[Méxiletine. Action on heart rhythm disorders].
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Clinical Trials as Topic; Drug E | 1975 |
Efficacy of combination therapy with mexiletine and a low dose of propranolol for premature ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Blood Pressure; Drug Therapy, Combination; Electrocardiography; F | 1990 |
Low dose quinidine-mexiletine combination therapy versus quinidine monotherapy for treatment of ventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography, | 1990 |
Conversion from intravenous to oral mexiletine in the acute management of repetitive ventricular arrhythmia.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Tria | 1985 |
[Comparison of mexiletine and dihydroquinidine in the treatment of ventricular asystolic arrhythmia].
Topics: Adult; Aged; Arrhythmias, Cardiac; Asthenia; Cardiac Complexes, Premature; Clinical Trials as Topic; | 1985 |
The role of antiarrhythmic drugs in prevention of sudden cardiac death.
Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Cardiac Comple | 1985 |
[Anti-arrhythmia effectiveness and tolerance of retard in comparison with standard mexiletine].
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Clinical Trials as Topic; Coronary | 1987 |
Efficacy of mexiletine in chronic ventricular arrhythmias: a multicentre double-blind medium-term trial.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Chronic Disease; | 1989 |
Mexiletine and tocainide: a comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Drug Evaluation; Drug Resistance; Drug Therapy | 1989 |
The effects of mexiletine on cardiac arrhythmias in patients with cor pulmonale.
Topics: Arrhythmias, Cardiac; Drug Evaluation; Female; Humans; Lung Diseases, Obstructive; Male; Mexiletine; | 1989 |
Mexiletine for the treatment of ventricular arrhythmias associated with chronic obstructive pulmonary disease.
Topics: Aged; Arrhythmias, Cardiac; Drug Evaluation; Electrocardiography; Female; Humans; Lung Diseases, Obs | 1989 |
[Effect of mexiletine on arrhythmia in patients with decompensated pulmonary heart disease].
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Female; Humans; Male; Mexiletine; Middl | 1988 |
Randomized controlled trial of prophylactic antiarrhythmic therapy in patients with inducible ventricular tachyarrhythmias after recent myocardial infarction.
Topics: Actuarial Analysis; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Electric Stimu | 1988 |
Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias.
Topics: Administration, Oral; Arrhythmias, Cardiac; Central Nervous System Diseases; Clinical Trials as Topi | 1987 |
[Antiarrhythmic efficacy and tolerance of slow-release mexiletine in comparison with hydroquinidine retard].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Delayed-Action Preparat | 1987 |
Mexiletine for arrhythmias.
Topics: Arrhythmias, Cardiac; Clinical Trials as Topic; Drug Interactions; Heart Ventricles; Humans; Kinetic | 1986 |
International Mexiletine and Placebo Antiarrhythmic Coronary Trial (IMPACT): II. Results from 24-hour electrocardiograms. IMPACT Research Group.
Topics: Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Double-Blind Method; Electrocardiograph | 1986 |
Relationship between plasma mexiletine levels at steady-state. Presence of ventricular arrhythmias and side effects.
Topics: Adult; Aged; Arrhythmias, Cardiac; Data Interpretation, Statistical; Female; Heart Ventricles; Human | 1987 |
Comparison of intravenous mexiletine and lidocaine for the treatment of ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Drug Evaluation; Electrocardiography; Female; Heart Ventricles; H | 1986 |
Usefulness and safety of cimetidine in patients receiving mexiletine for ventricular arrhythmia.
Topics: Aged; Arrhythmias, Cardiac; Cardiovascular System; Cimetidine; Clinical Trials as Topic; Double-Blin | 1985 |
[Experience with 7 year use of mexitil].
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Injection | 1985 |
Functional equality of coordinating centers in a multicenter clinical trial. Experience of the International Mexiletine and Placebo Antiarrhythmic Coronary Trial (IMPACT).
Topics: Arrhythmias, Cardiac; Chemistry, Clinical; Clinical Trials as Topic; Data Collection; Double-Blind M | 1986 |
196 other studies available for mexiletine and Arrhythmia
| Article | Year |
|---|---|
Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzoxepins; Chemical Phenomena; Chemistry; C | 1990 |
New antiarrhythmic agents. 2,2,5,5-Tetramethyl-3-pyrroline-3-carboxamides and 2,2,5,5-tetramethylpyrrolidine-3-carboxamindes.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation, Preclinical; Indicators and | 1986 |
Ten-year-old boy with congenital long QT syndrome type 2 (LQTS2) and life-threatening electrical storm: a case report of successful treatment with mexiletine.
Topics: Arrhythmias, Cardiac; Humans; Isoproterenol; Long QT Syndrome; Male; Mexiletine; Ventricular Fibrill | 2022 |
Mexiletine effectively prevented refractory Torsades de Pointes and ventricular fibrillation in a patient with congenital type 2 long QT syndrome.
Topics: Adult; Arrhythmias, Cardiac; DNA-Binding Proteins; Electrocardiography; Female; Humans; Long QT Synd | 2022 |
Reply to the Editor-Mexiletine in myotonic dystrophy: Beware of ventricular arrhythmias!
Topics: Arrhythmias, Cardiac; Humans; Mexiletine; Myotonic Dystrophy | 2021 |
To the Editor-Mexiletine in myotonic dystrophy: Beware of ventricular arrhythmias!
Topics: Arrhythmias, Cardiac; Humans; Mexiletine; Myotonic Dystrophy | 2021 |
Computational prediction of drug response in short QT syndrome type 1 based on measurements of compound effect in stem cell-derived cardiomyocytes.
Topics: Action Potentials; Adult; Ajmaline; Algorithms; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cell L | 2021 |
Broad antiarrhythmic effect of mexiletine in different arrhythmia models.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Disea | 2018 |
A case report: Is mexiletine usage effective in the shortening of QTC interval and improving the T-wave alternans in Timothy syndrome?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Autistic Disorder; Child, Preschool; Electrocardiograp | 2018 |
Drug-induced hypersensitivity syndrome complicated with concurrent fulminant type 1 diabetes mellitus and Hashimoto's thyroiditis.
Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Diabetes Mellitus, Type 1; Drug Hypersensitivity | 2013 |
Effects of Na+ channel blockers on extrasystolic stimulation-evoked changes in ventricular conduction and repolarization.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiological Pheno | 2014 |
Purkinje Cells as Sources of Arrhythmias in Long QT Syndrome Type 3.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Calcium; Cardiac Conduction System Disease; Heart | 2015 |
Myotonic dystrophy type 1.
Topics: Age of Onset; Anticipation, Genetic; Arrhythmias, Cardiac; Cause of Death; Humans; Mexiletine; Myoto | 2016 |
A case of mexiletine-induced hypersensitivity syndrome presenting as eosinophilic pneumonia.
Topics: Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Drug Hyper | 2010 |
A trafficking defective, Brugada syndrome-causing SCN5A mutation rescued by drugs.
Topics: Adolescent; Animals; Arrhythmias, Cardiac; Cell Line; Humans; Long QT Syndrome; Male; Mexiletine; Mu | 2004 |
A common cardiac sodium channel variant associated with sudden infant death in African Americans, SCN5A S1103Y.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Black or African American; Case-Control Studies | 2006 |
Partial expression defect for the SCN5A missense mutation G1406R depends on splice variant background Q1077 and rescue by mexiletine.
Topics: Alternative Splicing; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cell Line; Gene Expression Regul | 2006 |
Optical mapping of ventricular arrhythmias in LQTS mice with SCN5A mutation N1325S.
Topics: Animals; Arrhythmias, Cardiac; Asparagine; Cardiac Complexes, Premature; Long QT Syndrome; Mexiletin | 2007 |
New drugs in the management of ventricular arrhythmias.
Topics: Acecainide; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneac | 1984 |
Drugs and the heart. IV. Antiarrhythmic agents.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Br | 1980 |
Treatment of ventricular arrhythmias: role of mexiletine: symposium held under the patronage of the Belgian Society of Cardiology and organized by Boehringer Ingelheim.
Topics: Arrhythmias, Cardiac; Belgium; Cardiology; Congresses as Topic; Heart Ventricles; Humans; Mexiletine | 1980 |
Safe treatment of resistant ventricular arrhythmias with a combination of amiodarone and quinidine or mexiletine.
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Drug Therapy, Combination; Female; Heart | 1983 |
[Antiarrhythmic effect and influence on myocardial contractile function of the preparation, mexitil].
Topics: Adult; Animals; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Drug Evaluation; Drug Evaluation | 1980 |
[Oral maintenance treatment with mexiletine after acute administration of xilocaine (author's transl)].
Topics: Administration, Oral; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Female; Humans; Injections | 1981 |
[Mexiletine in treatment of chronic ventricular refractary arrhythmias (author's transl)].
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Female; Heart Ventricles; Humans; M | 1981 |
[Effectiveness of mexiletine in arrhythmia of effort].
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Drug Evaluati | 1981 |
[Mexiletine in the treatment of ventricular arrhythmias (author's transl)].
Topics: Arrhythmias, Cardiac; Cardiac Complexes, Premature; Child; Female; Heart Ventricles; Humans; Mexilet | 1982 |
[Anti-arrhythmic effects of mexiletine].
Topics: Administration, Oral; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Electrocardiography; | 1982 |
[Drug therapy of arrhythmia in coronary cardiopathy].
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Benzeneacetamides; Cardiac Comp | 1983 |
[Injectable mexiletine and disorders of the auricular rhythm].
Topics: Adult; Aged; Arrhythmias, Cardiac; Atrial Flutter; Cardiac Complexes, Premature; Female; Heart Atria | 1983 |
[Antiarrhythmic efficacy of mexiletine in supraventricular arrhythmias, Wolff-Parkinson-White syndrome and persistent iterative ventricular hyperkinetic arrhythmias. Considerations on these less noted therapeutic effects].
Topics: Adult; Aged; Arrhythmias, Cardiac; Child; Drug Evaluation; Female; Humans; Male; Mexiletine; Middle | 1984 |
Nursing care for survivors of sudden cardiac death.
Topics: Adaptation, Psychological; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Arrest; H | 1984 |
Increased incidence of side effects after encainide: a newly developed antiarrhythmic drug.
Topics: Adult; Aged; Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Encainide; | 1984 |
Drug therapy of cardiac arrhythmias.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Biological Availabili | 1983 |
Mexiletine for recurring ventricular arrhythmias: assessment by long-term electrocardiographic recordings and sequential electrophysiologic studies.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Electrocardiography; Female; Heart; H | 1984 |
Effects of oral mexiletine on left and right ventricular function.
Topics: Adult; Arrhythmias, Cardiac; Cardiac Output; Exercise Test; Female; Heart Rate; Heart Ventricles; Hu | 1984 |
Hemodynamic effects of antiarrhythmic drugs in acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Cardiac Output; Central Ve | 1984 |
Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Female; Humans; Kinetics; Male; Mexiletine; Midd | 1984 |
Mexiletine in refractory ventricular arrhythmias.
Topics: Aged; Arrhythmias, Cardiac; Drug Evaluation; Electrocardiography; Female; Humans; Male; Mexiletine; | 1983 |
Increase of mexiletine plasma levels due to delayed hepatic metabolism in patients with chronic liver disease.
Topics: Arrhythmias, Cardiac; Chronic Disease; Heart Failure; Humans; Kidney Diseases; Kinetics; Liver; Live | 1983 |
[The anti-arrhythmic action of mexiletine: experimental study].
Topics: Animals; Arrhythmias, Cardiac; Barium; Chlorides; Mexiletine; Propylamines; Rabbits | 1983 |
[Mexiletine: electrophysiologic effects].
Topics: Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Block; Heart Conduction System; Human | 1983 |
[Hemodynamic and electrophysiological effects of intravenous injection of mexiletine].
Topics: Adult; Aged; Arrhythmias, Cardiac; Female; Heart Conduction System; Hemodynamics; Humans; Infusions, | 1983 |
Improved liquid-chromatographic determination of mexiletine, an antiarrhythmic drug, in plasma.
Topics: Animals; Arrhythmias, Cardiac; Cattle; Chromatography, Liquid; Humans; Kinetics; Mexiletine; Propyla | 1984 |
The interaction of mexiletine with other cardiovascular drugs.
Topics: Absorption; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Interactions; Drug Therapy, Combinati | 1984 |
Long-term mexiletine for ventricular arrhythmia.
Topics: Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Drug Evaluation; Electrophysiology; Female; | 1984 |
Long-term clinical experience with mexiletine.
Topics: Administration, Oral; Aged; Arrhythmias, Cardiac; Drug Evaluation; Female; Follow-Up Studies; Humans | 1984 |
Suppression of high-grade ventricular ectopic activity by antiarrhythmic drug treatment as a marker for survival in patients with chronic coronary artery disease.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Female; Hum | 1984 |
A study to compare the efficacy, plasma concentration profile and tolerability of conventional mexiletine and slow-release mexiletine.
Topics: Administration, Oral; Aged; Arrhythmias, Cardiac; Delayed-Action Preparations; Drug Evaluation; Elec | 1984 |
New drugs for treating cardiac arrhythmias.
Topics: Acebutolol; Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Encainide | 1981 |
Mexiletine for ventricular arrhythmias.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Arrhythmias, Cardiac; Blood Pressure; Dose-Response Relati | 1981 |
Clinical pharmacology of antiarrhythmic drugs: a review and overview, part II.
Topics: Amiodarone; Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disopyramide; Humans; | 1981 |
Advances in antiarrhythmic therapy. The role of newer antiarrhythmic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Atrioventricular Node; Humans; | 1982 |
[Determination of plasma concentrations of anti-arrhythmia agents].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Biological Availability; Disopyramide; Dose-Response R | 1981 |
Tocainide--an alternative to mexiletine.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Lidocaine; Mexiletine; Tocainide | 1982 |
Quantitative analysis of the antiarrhythmic effect of drugs on canine ventricular arrhythmias by the determination of minimum effective plasma concentrations.
Topics: Animals; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disopyramide; Dogs; Female; Lidoca | 1983 |
Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine.
Topics: Arrhythmias, Cardiac; Coronary Disease; Diarrhea; Dose-Response Relationship, Drug; Drug Therapy, Co | 1983 |
Absorption and antiarrhythmic efficacy of sustained-release mexiletine.
Topics: Absorption; Adult; Arrhythmias, Cardiac; Capsules; Delayed-Action Preparations; Digestive System; Fe | 1983 |
[Validity and limits of invasive pharmacological tests in the treatment of malignant ventricular hyperkinetic arrhythmias].
Topics: Adult; Aged; Ajmaline; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Fe | 1983 |
Simultaneous plasma levels determination of mexiletine and one of its metabolites by electron capture gas-liquid chromatography.
Topics: Arrhythmias, Cardiac; Biotransformation; Chemical Phenomena; Chemistry; Chromatography, Gas; Gas Chr | 1982 |
Mexiletine in the treatment of ventricular arrhythmias.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Female; Heart Arrest; Heart Ventricles; Hum | 1980 |
Clinical efficacy of antiarrhythmic drugs in prevention of sudden coronary death.
Topics: Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Coronary Angiography; Coronary Artery Bypas | 1982 |
[Mexiletine in the treatment of ventricular rhythm disorders].
Topics: Arrhythmias, Cardiac; Child; Female; Heart Ventricles; Humans; Male; Mexiletine; Propylamines | 1982 |
New antiarrhythmic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduction System; Humans; Mexiletin | 1982 |
Population pharmacokinetic parameters in patients treated with oral mexiletine.
Topics: Aged; Arrhythmias, Cardiac; Female; Humans; Kinetics; Male; Mexiletine; Middle Aged; Propylamines | 1982 |
[The effect of disopyramide, mexiletine and propafenon after intravenous and oral administration on left ventricular function in the M-mode echocardiogram].
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Drug Therap | 1982 |
[Efficacy of mexiletine in the treatment of ventricular arrhythmia in patients with conduction disorders and sick sinus syndrome].
Topics: Adult; Aged; Arrhythmias, Cardiac; Female; Heart Block; Heart Conduction System; Heart Rate; Humans; | 1982 |
Electrophysiologic effects of mexiletine in children.
Topics: Adolescent; Arrhythmias, Cardiac; Atrioventricular Node; Bundle of His; Child; Child, Preschool; Fem | 1982 |
[Mexiletine, a new anti-arrhythmic, in the treatment of ventricular arrhythmia].
Topics: Administration, Oral; Adolescent; Adult; Aged; Arrhythmias, Cardiac; Drug Evaluation; Female; Humans | 1982 |
Influence of an antiarrhythmic premedication on the development of premature ventricular contractions during fiberoptic gastroduodenoscopy.
Topics: Arrhythmias, Cardiac; Blood Pressure; Duodenoscopy; Electrocardiography; Gastroscopy; Heart Ventricl | 1981 |
[Hemodynamic effects of a new anti-arrhythmia agent: mexiletine].
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Cardiac Catheterization; Female; Hemodynamics; Humans; Male | 1980 |
[Effect of using a mexitil preparation in cardiac rhythm disorders].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Evaluation; Female; Humans; Infusion | 1981 |
[Antiarrhythmic treatment with mexiletine in acute myocardial infarction (author's transl)].
Topics: Aged; Arrhythmias, Cardiac; Female; Humans; Lidocaine; Male; Mexiletine; Middle Aged; Myocardial Inf | 1981 |
[Efficacy of disopyramide and mexiletine per os in the chronic treatment of ventricular arrhythmias sensitive to lidocaine].
Topics: Arrhythmias, Cardiac; Disopyramide; Humans; Lidocaine; Mexiletine; Middle Aged; Propylamines; Pyridi | 1981 |
Mexiletine in the treatment of refractory ventricular arrhythmias: a report of five cases.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Humans; | 1980 |
Electrophysiological properties of mexiletine assessed with respect to plasma concentrations.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Electrophysiology; Female; Heart; Heart Conduction System; | 1980 |
[Experience with mexiletin in the treatment of ventricular arrhythmias (author's transl)].
Topics: Aged; Arrhythmias, Cardiac; Coronary Disease; Female; Heart Ventricles; Humans; Male; Mexiletine; Mi | 1980 |
Mexiletine for ventricular arrhythmia after repair of tetralogy of Fallot.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Electrocardiography; Heart Ventricles; Humans; Infant, Newb | 1980 |
[The new antiarrhythmia drugs disopyramide and mexiletine].
Topics: Arrhythmias, Cardiac; Disopyramide; Humans; Mexiletine; Propylamines; Pyridines | 1980 |
Mexiletine for refractory-ventricular arrhythmias: results using serial electrophysiologic testing.
Topics: Aged; Arrhythmias, Cardiac; Electrophysiology; Female; Humans; Male; Mexiletine; Middle Aged; Propyl | 1981 |
Carbamate analogues of tocainide.
Topics: Aconitine; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Carbamates; C | 1994 |
Effects of NS-2, a new class 1 antiarrhythmic agent, and AFD-19, its active metabolite, on ventricular arrhythmias induced by coronary artery occlusion and reperfusion in anesthetized rats: comparison with disopyramide and mexiletine.
Topics: Amino Alcohols; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Coronary Dise | 1994 |
A comparative studies of antiarrhythmic activity of Mexicord-Poland and its foreign counterpart.
Topics: Aconitine; Animals; Arrhythmias, Cardiac; Barium Compounds; Chlorides; Digoxin; Electrocardiography; | 1993 |
Clinical evaluation of the use-dependent QRS prolongation and the reverse use-dependent QT prolongation of class I and class III antiarrhythmic agents and their value in predicting efficacy.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Drug Evaluation; Electrocar | 1993 |
Suppression of ventricular premature contractions continues after the washout of antiarrhythmic drugs.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atenolol; Disopyramide; Electrocardiograp | 1993 |
Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory act
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cyclooxygenase | 1996 |
Mexiletine in the treatment of resistant ventricular arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Ventricles; Humans; Mexiletine | 1996 |
Population pharmacokinetic analysis of mexiletine in adult arrhythmic patients in Japanese population.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; H | 1998 |
Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Coronary Vessels; Dogs; Dose- | 1998 |
Lack of interaction between amiodarone and mexiletine in cardiac arrhythmia patients.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bayes Theorem; Biological Availabili | 2002 |
The development of mexiletine in the management of ventricular dysrhythmias.
Topics: Arrhythmias, Cardiac; Cardiac Complexes, Premature; Female; Heart Ventricles; Humans; Male; Mexileti | 1977 |
[Treatment of rhythm disorders of ventricular origin with KO 1173 (Mexiletin) (author's transl)].
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Female; Human | 1977 |
The efficacy of intravenous mexiletine on ventricular ectopic activity.
Topics: Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Drug Evaluation; Female; Heart Ventricles; | 1977 |
[Clinical study of the antiarrhythmic action of Mexityl in ventricular disorders of the cardiac rhythm].
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Drug Evaluation; | 1979 |
Newer antiarrhythmic drugs.
Topics: Administration, Oral; Adult; Amiodarone; Animals; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Ca | 1978 |
[Effects of mexiletine and lidocaine on myocardial performance in heart disease patients in various functional classes].
Topics: Adult; Arrhythmias, Cardiac; Cardiac Output; Coronary Disease; Heart Diseases; Heart Rate; Humans; L | 1978 |
Long term oral antiarrhythmic therapy with mexiletine.
Topics: Administration, Oral; Arrhythmias, Cardiac; Humans; Long-Term Care; Mexiletine; Propylamines | 1977 |
Long term treatment of ventricular arrhythmias with oral mexiletine.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Heart Ventricles; Humans; Long-Term Care; M | 1977 |
Mexiletine.
Topics: Arrhythmias, Cardiac; Central Nervous System; Digestive System; Heart Conduction System; Hemodynamic | 1979 |
Mexiletine in treatment of ventricular arrhythmias. A long-term follow-up.
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Chromatography, Gas; Drug Evaluation; Female; Follow- | 1979 |
Mexiletine. Use in control of chronic drug-resistant ventricular arrhythmia.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Drug Tolerance; Female; | 1979 |
Effect of mexiletine on monophasic action potentials recorded from the right ventricle in man.
Topics: Action Potentials; Adult; Arrhythmias, Cardiac; Cardiac Catheterization; Cardiac Pacing, Artificial; | 1979 |
Effect of mexiletine on conduction of premature ventricular beats in man: a study using monophasic action potential recordings from the right ventricle.
Topics: Action Potentials; Adult; Arrhythmias, Cardiac; Cardiac Catheterization; Cardiac Pacing, Artificial; | 1979 |
[The effects of intravenous mexiletine on cardiac performance (author's transl)].
Topics: Adult; Arrhythmias, Cardiac; Drug Evaluation; Humans; Injections, Intravenous; Male; Mexiletine; Mid | 1979 |
[Treatment of arrhythmia due to heart surgery by means of mexiletine].
Topics: Arrhythmias, Cardiac; Cardiac Surgical Procedures; Humans; Mexiletine; Propylamines | 1979 |
Mexiletine in the management of ventricular dysrhythmias.
Topics: Administration, Oral; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Drug Resistance; Human | 1977 |
[The influence of mexiletin on ventricular arrhythmias during ergometric exercise (author's transl)].
Topics: Arrhythmias, Cardiac; Blood Pressure; Female; Heart Rate; Humans; Male; Mexiletine; Middle Aged; Nau | 1977 |
[The long QT syndrome. Calculation of the effective refractory period of the right ventricle].
Topics: Adult; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Conduction System; Heart Ventricles; | 1977 |
[Mexiletine--findings in animal experiments on its antiarrhythmic and electrophysiological effects in the heart (author's transl)].
Topics: Animals; Arrhythmias, Cardiac; Calcium; Dogs; Heart; Heart Atria; Heart Ventricles; Mexiletine; Prop | 1978 |
Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.
Topics: Acebutolol; Amiodarone; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Bretylium Compounds | 1978 |
[Mexiletine in supraventricular arrhythmias].
Topics: Aged; Arrhythmias, Cardiac; Electrocardiography; Humans; Mexiletine; Myocardial Infarction; Propylam | 1978 |
[Experience with mexiletine in the occurrence of ventricular arrhythmias in the acute phase of myocardial infarct].
Topics: Acute Disease; Aged; Arrhythmias, Cardiac; Heart Ventricles; Humans; Male; Mexiletine; Middle Aged; | 1978 |
Long-term oral antiarrhythmic therapy with mexiletine.
Topics: Administration, Oral; Arrhythmias, Cardiac; Coronary Disease; Female; Humans; Male; Mexiletine; Midd | 1978 |
New antiarrhythmic drugs.
Topics: Amiodarone; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Humans; Lidocaine; Mexiletine; | 1978 |
[The effect of the new antiarrhythmic drug mexiletine on sinus node and intracardiac conduction in man (author's transl)].
Topics: Arrhythmias, Cardiac; Electrocardiography; Electrophysiology; Heart Conduction System; Humans; Mexil | 1978 |
[Side effects after long-term administration of mexiletine].
Topics: Arrhythmias, Cardiac; Drug Administration Schedule; Female; Humans; Male; Mexiletine; Middle Aged; N | 1978 |
The development of mexiletine in the treatment of cardiac arrhythmias.
Topics: Arrhythmias, Cardiac; Humans; Mexiletine; Myocardial Infarction; Propylamines | 1977 |
The use of mexiletine at the Ulster Hospital, Belfast.
Topics: Adult; Aged; Arrhythmias, Cardiac; Drug Tolerance; Female; Humans; Male; Mexiletine; Middle Aged; My | 1977 |
Oral dosage schedules for mexiletine.
Topics: Administration, Oral; Arrhythmias, Cardiac; Drug Administration Schedule; Humans; Intestinal Absorpt | 1977 |
Comparison of the effects of lignocaine and mexiletine on experimental ventricular arrhythmias.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Lidocaine; Mexiletine; Propylamines; Tachycardia; Ventricular F | 1977 |
Varicella myocarditis presenting with unusual ventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Chickenpox; Child; Electrocardiography; Heart Ventricles; Humans; Male; Mexile | 1977 |
Mexiletine for ventricular arrhythmias.
Topics: Arrhythmias, Cardiac; Humans; Mexiletine; Propylamines | 1976 |
Proceedings: Comparison of mexiletine and procainamide in prevention of recurrent ventricular arrhythmias after acute myocardial infarction.
Topics: Arrhythmias, Cardiac; Electrocardiography; Heart Ventricles; Humans; Male; Mexiletine; Myocardial In | 1975 |
Haemodynamic effects of a new anti-arrhythmic agent, mexiletine (Kö 1173) in ischaemic heart disease.
Topics: Arrhythmias, Cardiac; Blood Pressure; Brachial Artery; Cardiac Output; Coronary Disease; Heart Rate; | 1975 |
Mexiletine and propafenone: a comparative study of monotherapy, low, and full dose combination therapy.
Topics: Arrhythmias, Cardiac; Cardiac Complexes, Premature; Drug Therapy, Combination; Electrocardiography; | 1992 |
[Clinical significance of the use-dependent sodium channel block and reverse use-dependent potassium channel block of class I and class III antiarrhythmic agents and their values to predict drug efficacy].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disopyramide; Drug Evaluation; Electrocardiography, Am | 1992 |
Antiarrhythmic, electrophysiological and haemodynamic effects of prolonged oral dosing with Org 7797 in the anaesthetized rat.
Topics: Action Potentials; Administration, Oral; Anesthesia; Animals; Anti-Arrhythmia Agents; Arrhythmias, C | 1992 |
[Anti-arrhythmia agents in heart failure].
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; C | 1992 |
The effect of pretreatment with moricizine on early arrhythmia resulting from myocardial ischemia in rats.
Topics: Animals; Arrhythmias, Cardiac; Coronary Disease; Disopyramide; Hemodynamics; Male; Mexiletine; Moric | 1992 |
Functional and metabolic effects of mexiletine in the rat heart-lung preparation.
Topics: Adenosine Triphosphate; Animals; Arrhythmias, Cardiac; Cardiac Output; Dose-Response Relationship, D | 1992 |
[Evaluation of risks and treatment of asymptomatic ventricular arrhythmias].
Topics: Adult; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Electrocardiography, Ambulatory; Female; | 1990 |
Antiarrhythmic and cardiovascular profiles of the fused indole compound (3aR,12R,12aR,12bS)-12-amino-2,3,3a,4,11,12,12a,12b-octahydro-10-hydrox yisoquino [2,1,8-lma]carbazol-5(1H)-one hydrochloride 1.5 hydrate.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Carbazoles; Chloroform; Disopyramide; Dogs; F | 1991 |
Anti-arrhythmic activities of six indole derivatives of changrolin.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Guinea Pigs; Indoles; Mexiletine; Myocardial | 1991 |
Generalized drug eruption due to mexiletine hydrochloride: topical provocation on previously involved skin.
Topics: Administration, Cutaneous; Aged; Arrhythmias, Cardiac; Drug Eruptions; Humans; Male; Mexiletine; Ski | 1991 |
[Primary research on the clinical significance of ventricular late potentials (VLPs), and the impact of mexiletine, lidocaine and Astragalus membranaceus on VLPs].
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Astragalus propinquus; Drugs, Chinese Herbal; | 1991 |
[Comment on the publication by J. Weirich and H. Antoni "Current aspects on the rate-dependent effect of Class-1 anti-arrhythmia agents. Critical analysis of the usual subclassification" in Z Kardiol 80:177-186 (1991)].
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Mexiletine | 1991 |
Combination antiarrhythmic treatment among class Ia, Ib, and II agents for ventricular arrhythmias.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Disopyramide; Drug Administration Schedule; | 1991 |
[Therapeutic drug monitoring of disopyramide, mexiletine, aprindine and beta blockers].
Topics: Adrenergic beta-Antagonists; Aprindine; Arrhythmias, Cardiac; Biological Availability; Chromatograph | 1990 |
Pharmacologic modifications of reperfusion arrhythmias in the dog in vivo: possible relation to limitation of the extent of infarction.
Topics: Animals; Arrhythmias, Cardiac; Butylated Hydroxytoluene; Dogs; Drug Therapy, Combination; Electrocar | 1990 |
[Mexiletine in patients with progressive infarction and reduced ventricular function: anti-arrhythmic efficacy and hemodynamic effects].
Topics: Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Ventricles; Hemodynamics; Humans; Mal | 1990 |
Mexiletine. Long-term efficacy and side effects in patients with chronic drug-resistant potentially lethal ventricular arrhythmias.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; | 1990 |
Effects of mexiletine on delayed after-depolarization and triggered activity.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Electric Stimulation; Heart; Heart Conduction Syst | 1990 |
Analysis of ventricular arrhythmias in patients with dilated cardiomyopathy--relationship between the effects of antiarrhythmic agents and severity of myocardial lesions.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Cardiomyopathy, Dilated; Disop | 1990 |
Antiarrhythmic drugs. Clinical pharmacology of the old and the new agents.
Topics: Acecainide; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden; Delayed-Action | 1985 |
[Mexiletine in the acute treatment of ventricular arrhythmias in cardiosurgery].
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Cardiac Surgical Procedures; Female | 1985 |
Effectiveness of mexiletine in ventricular arrhythmias.
Topics: Adult; Aged; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Electrocardiography; Female; Heart | 1985 |
Experimental evidence for the antiarrhythmic action of indoramin.
Topics: Animals; Arrhythmias, Cardiac; Blood Pressure; Cats; Coronary Vessels; Electrocardiography; Guinea P | 1986 |
[Experience with the combined use of 1st- and 2d-group anti-arrhythmic preparations in patients with refractory arrhythmia].
Topics: Aconitine; Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Drug E | 1988 |
Combination antiarrhythmic therapy for management of malignant ventricular arrhythmia.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Complexes, Premature; Drug Therapy, Combinatio | 1988 |
Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Cardiac Complexes, Premature; Dru | 1985 |
Evaluation of antiarrhythmic drug efficacy using holter electrocardiographic technique.
Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Cardiac Complexes, | 1985 |
[Reperfusion syndrome during thrombolytic therapy of myocardial infarct].
Topics: Arrhythmias, Cardiac; Female; Fibrinolytic Agents; Hemodynamics; Humans; Male; Mexiletine; Middle Ag | 1989 |
[Mexiletine in terminal renal failure and various dialysis procedures].
Topics: Adult; Aged; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Female; Heart Ventricles; Hemof | 1989 |
Mexiletine-quinidine combination: enhanced antiarrhythmic and electrophysiologic activity in the dog.
Topics: Animals; Arrhythmias, Cardiac; Dogs; Drug Synergism; Drug Therapy, Combination; Heart Conduction Sys | 1989 |
[Changes in thrombocyte-vascular hemostasis and cyclic nucleotide levels after anti-arrhythmia therapy in patients with ischemic heart disease].
Topics: Adult; Aged; Arrhythmias, Cardiac; Coronary Disease; Disopyramide; Female; Humans; Male; Mexiletine; | 1989 |
[Effect of mexiletine on human atrial vulnerability].
Topics: Adult; Aged; Arrhythmias, Cardiac; Electrophysiology; Female; Heart Atria; Humans; Male; Mexiletine; | 1989 |
Mexiletine therapy in patients with chronic drug-resistant malignant ventricular arrhythmias. Clinical efficacy, safety, and side effects.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Chronic Disease; Death, Sudden; Dizz | 1986 |
Combination of disopyramide and mexiletine for better tolerance and additive effects for treatment of ventricular arrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Disopyramide; Drug Therapy, Combination; Elect | 1989 |
Prolongation of ventricular depolarization. ECG manifestation of mexiletine toxicity.
Topics: Aged; Arrhythmias, Cardiac; Electrocardiography; Female; Heart Conduction System; Humans; Kidney Fai | 1989 |
Proarrhythmia related to a kinetic and dynamic interaction of mexiletine and theophylline.
Topics: Arrhythmias, Cardiac; Drug Interactions; Electrocardiography; Humans; Male; Mexiletine; Middle Aged; | 1989 |
Mexiletine and tocainide: does response to one predict response to the other?
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electric Stimulation; Electrocardiography | 1986 |
Newer antiarrhythmic drugs in children.
Topics: Adolescent; Adult; Amiodarone; Anilides; Arrhythmias, Cardiac; Child; Child, Preschool; Electrocardi | 1987 |
Mexiletine and tocainide: a profile of two lidocaine analogs.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Heart; Humans; In Vitro Te | 1987 |
Antiarrhythmic efficacy of penticainide and comparison with disopyramide, flecainide, propafenone and mexiletine by acute oral drug testing.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chronic Disease; Di | 1987 |
Clinical predictors of arrhythmia worsening by antiarrhythmic drugs.
Topics: Anilides; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Coronary Disease; Electrocardiography; Encai | 1988 |
[Worsening of ventricular arrhythmia in the dynamic ECG in patients treated with anti-arrhythmia drugs].
Topics: Adolescent; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Therapy, Com | 1988 |
Prediction of efficacy and tolerance of oral mexiletine by intravenous lidocaine application.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Female; Humans; Injections, Intravenous; Li | 1988 |
[Treatment of ventricular arrhythmia with mexiletine (Mexitil), monitored by Holter ambulatory electrocardiography].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Drug Evaluation; Drug To | 1988 |
Electrophysiological mechanism for the antiarrhythmic action of propafenone: a comparison with mexiletine.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Guinea Pigs; Heart; In Vit | 1988 |
Mexilitene use in pregnancy.
Topics: Adult; Arrhythmias, Cardiac; Dose-Response Relationship, Drug; Female; Heart Ventricles; Humans; Mex | 1988 |
Therapeutic effectiveness and plasma levels of single or combination use of class I antiarrhythmic agents for ventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Chronic Disease; Disopyramide; | 1988 |
Comparison of the effects of calcium channel blockers and antiarrhythmic drugs on digitalis-induced oscillatory afterpotentials on canine Purkinje fiber.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; Digitalis; Diltiaze | 1987 |
Arrhythmogenesis--a European perspective.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Utilization; Europe; Humans; Mexileti | 1987 |
Pharmacological investigation of a new anti-arrhythmic agent, GYKI-23 107.
Topics: Aconitum; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cats; Chemical Phenomena; Chemistry | 1987 |
Antiarrhythmic effects of a novel diamine derivative, AN-132, on several animal models of cardiac arrhythmias.
Topics: Aconitine; Anilides; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Chloroform; Disopyramide | 1987 |
Mexiletine use in pregnancy and lactation.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Fetus; Humans; Mexiletine; Milk, Human; | 1987 |
Influence of mexiletine on caffeine elimination.
Topics: Adult; Aged; Arrhythmias, Cardiac; Caffeine; Female; Half-Life; Humans; Kinetics; Male; Mexiletine; | 1987 |
Mexiletine: an effective antiarrhythmic drug for treatment of ventricular arrhythmias in congenital heart disease.
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Child; Child, Preschool; Electrocardiography; Heart Defects | 1987 |
[The effects and pharmacokinetics of mexiletine in ventricular arrhythmia in maintenance hemodialysis patients].
Topics: Aged; Arrhythmias, Cardiac; Female; Humans; Kidney Failure, Chronic; Male; Mexiletine; Middle Aged; | 1987 |
[Mexiletine in the treatment of ventricular arrhythmias].
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Child; Disopyramide; Drug Evaluation; Electrocardiogr | 1986 |
An experimental approach to the choice of antiarrhythmic therapy.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cats; Coronary Disease; Diltiazem | 1986 |
[Anti-arrhythmic efficacy of the amiodarone-mexiletine combination in the treatment of resistant complex ventricular arrhythmias].
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Drug Therapy, Combination; Electrocardio | 1986 |
New antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Flecainide; Humans; Kinetics; Mexiletine; | 1986 |
Effect of mexiletine on reperfusion-induced ventricular arrhythmias: comparison with lidocaine.
Topics: Animals; Arrhythmias, Cardiac; Constriction; Coronary Circulation; Coronary Vessels; Dogs; Female; H | 1986 |
Aggravation of ventricular arrhythmia. A drug-induced complication.
Topics: Anilides; Anti-Arrhythmia Agents; Aprindine; Arrhythmias, Cardiac; Disopyramide; Drug Evaluation; El | 1985 |
[Preclinical study of the pharmacodynamic and toxicologic effects of the antiarrhythmic agent, mexiletine].
Topics: Animals; Arrhythmias, Cardiac; Dogs; Female; Guinea Pigs; Heart Rate; Lethal Dose 50; Male; Mexileti | 1986 |
Comparative antiarrhythmic efficacy of verapamil, 17-monochloracetylajmaline, mexiletine and amiodarone in patients with severe chagasic myocarditis: relation with the underlying arrhythmogenic mechanisms.
Topics: Adult; Ajmaline; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Chagas Cardiomyopathy; Female; Human | 1986 |
The effect of antiarrhythmic drugs on life-threatening arrhythmias induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cats; Coronary Disease; Disease M | 1985 |
[Early interruption of antiarrhythmia treatment in the acute phase of infarction complicated by ventricular arrhythmia].
Topics: Arrhythmias, Cardiac; Drug Administration Schedule; Female; Humans; Male; Mexiletine; Middle Aged; M | 1985 |
Antifibrillatory properties of alinidine after coronary artery occlusion in rats.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiovascular Agents; Clonidine; Coronary Di | 1985 |
Limitations of failure of procainamide during electrophysiologic testing to predict response to other medical therapy.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; E | 1985 |
Clinical evaluation of oral mexiletine therapy in the treatment of ventricular arrhythmias.
Topics: Administration, Oral; Adult; Aged; Arrhythmias, Cardiac; Female; Humans; Male; Mexiletine; Middle Ag | 1985 |
[Monitoring of anti-arrhythmia drugs with the Holter system and the determination of their blood levels (mexiletine (mexitil) and amiodarone)].
Topics: Adult; Aged; Amiodarone; Arrhythmias, Cardiac; Benzofurans; Drug Evaluation; Drug Tolerance; Electro | 1985 |
Inhibition of sympathetic nervous system by mexiletine, an antiarrhythmic agent, and its antagonism against ouabain.
Topics: Animals; Aorta, Thoracic; Arrhythmias, Cardiac; Electric Stimulation; Epinephrine; Guinea Pigs; In V | 1985 |
The yield of programmed ventricular stimulation in mitral valve prolapse patients with ventricular arrhythmias.
Topics: Adult; Amiodarone; Arrhythmias, Cardiac; Electrocardiography; Electrophysiology; Female; Heart Arres | 1985 |
Electrophysiological mechanisms for the antiarrhythmic action of mexiletine on digitalis-, reperfusion- and reoxygenation-induced arrhythmias.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Barium; Coronary Circulation; Depression, Chemical | 1985 |